<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Brain Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Brain Sci</journal-id>
<journal-id journal-id-type="publisher-id">brainsci</journal-id>
<journal-title-group>
<journal-title>Brain Sciences</journal-title>
</journal-title-group>
<issn pub-type="epub">2076-3425</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32272607</article-id>
<article-id pub-id-type="pmc">7226342</article-id>
<article-id pub-id-type="doi">10.3390/brainsci10040219</article-id>
<article-id pub-id-type="publisher-id">brainsci-10-00219</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Efficacy and Safety of Melatonin Treatment in Children with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder—A Review of the Literature</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4511-2669</contrib-id>
<name>
<surname>Rzepka-Migut</surname>
<given-names>Beata</given-names>
</name>
<xref ref-type="aff" rid="af1-brainsci-10-00219">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1794-8546</contrib-id>
<name>
<surname>Paprocka</surname>
<given-names>Justyna</given-names>
</name>
<xref ref-type="aff" rid="af2-brainsci-10-00219">2</xref>
<xref ref-type="corresp" rid="c1-brainsci-10-00219">*</xref>
</contrib>
</contrib-group>
<aff id="af1-brainsci-10-00219"><label>1</label>Department of Pediatric Neurology and Pediatrics, St. Queen Jadwiga’s Regional Clinical Hospital No 2, 35-301 Rzeszów, Poland; <email>beata-rzepka@o2.pl</email></aff>
<aff id="af2-brainsci-10-00219"><label>2</label>Department of Pediatric Neurology, Faculty of Medical Science in Katowice, Medical University of Silesia, 40-752 Katowice, Poland</aff>
<author-notes>
<corresp id="c1-brainsci-10-00219"><label>*</label>Correspondence: <email>justyna.paprocka@interia.pl</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>07</day>
<month>4</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<month>4</month>
<year>2020</year>
</pub-date>
<volume>10</volume>
<issue>4</issue>
<elocation-id>219</elocation-id>
<history>
<date date-type="received">
<day>07</day>
<month>2</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>3</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 by the authors.</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) are neurodevelopmental disorders with disturbed melatonin secretion profile and sleep problems. The growing incidence of ASD and ADHD inspires scientists to research the underlying causes of these conditions. The authors focused on two fundamental aspects, the first one being the presentation of the role of melatonin in ASD and ADHD and the second of the influence of melatonin treatment on sleep disorders. The authors present the use of melatonin both in the context of causal and symptomatic treatment and discuss melatonin supplementation: Dosage patterns, effectiveness, and safety. Sleep disorders may have a different clinical picture, so the assessment of exogenous melatonin efficacy should also refer to a specific group of symptoms. The review draws attention to the wide range of doses of melatonin used in supplementation and the need to introduce unified standards especially in the group of pediatric patients.</p>
</abstract>
<kwd-group>
<kwd>melatonin</kwd>
<kwd>autism spectrum disorder (ASD) attention deficit hyperactivity disorder (ADHD)</kwd>
<kwd>sleep disorders</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-brainsci-10-00219" sec-type="intro">
<title>1. Introduction</title>
<p>The circadian rhythm allows organisms to adapt to the changing environmental conditions resulting from the day and night cycle. The organic chemical compound N-acetyl-5-methoxytryptamine called melatonin is the main regulator of circadian rhythm and was first isolated in 1958. 62 years of intensive research provided us with information on the metabolism and function.</p>
<p>Melatonin (MLT) is a naturally synthesized hormone secreted mainly from the pineal gland and its production is suppressed by light. It participates in the regulation of behavioral and physiological processes, including sleep and wakefulness cycle and adaptation to seasonal changes [<xref ref-type="bibr" rid="B1-brainsci-10-00219">1</xref>]. Good quality sleep contributes to better functioning, improvement in well-being, and in cognitive functions. Poor quality of sleep can be manifested by deteriorated concentration, emotional liability, impulsive behavior [<xref ref-type="bibr" rid="B2-brainsci-10-00219">2</xref>] and can also lead to a decrease in energy, anxiety, irritability, and fatigue [<xref ref-type="bibr" rid="B3-brainsci-10-00219">3</xref>]. Sleep problems affect about 20%–40% of healthy children [<xref ref-type="bibr" rid="B4-brainsci-10-00219">4</xref>]. This problem is particularly pronounced in the group of children with neurodevelopmental diseases [<xref ref-type="bibr" rid="B5-brainsci-10-00219">5</xref>] and may be related to even 80% of patients [<xref ref-type="bibr" rid="B6-brainsci-10-00219">6</xref>,<xref ref-type="bibr" rid="B7-brainsci-10-00219">7</xref>]. In pediatric practice, three groups of disorders that are most often associated with sleep disorders include ADHD, autism and mood/anxiety disorders [<xref ref-type="bibr" rid="B8-brainsci-10-00219">8</xref>]. The authors focused on the two most common disease entities, which are characterized by distorted judgment of reality in situations requiring flexibility and behavioral problems [<xref ref-type="bibr" rid="B9-brainsci-10-00219">9</xref>]. In the presented disorders, the clinical picture is heterogeneous [<xref ref-type="bibr" rid="B10-brainsci-10-00219">10</xref>] and the etiology is still unclear [<xref ref-type="bibr" rid="B11-brainsci-10-00219">11</xref>].</p>
<p>Autism spectrum disorder (ASD) can be defined based on the diagnostic criteria which include communication and social interaction disorders and limited repetitive patterns of behavior and interests. In addition to the fundamental symptoms, many patients also present with anxiety attacks, (self)-aggression, mood disorders, and sleep difficulties [<xref ref-type="bibr" rid="B12-brainsci-10-00219">12</xref>,<xref ref-type="bibr" rid="B13-brainsci-10-00219">13</xref>]. The first symptoms of autism are observed already in early childhood and usually persist throughout life. An increase in the incidence of ASD has been reported over recent years. According to the CDC’s Autism and Developmental Disabilities Monitoring (ADDM) report in 2000 the incidence of ASD was estimated at 1 in 150 children, in 2014 this incidence was 1 diagnosis in 59 children at the age of 8 [<xref ref-type="bibr" rid="B14-brainsci-10-00219">14</xref>]. The causes of this tendency may be different, e.g., a higher standard of medical and diagnostic care [<xref ref-type="bibr" rid="B15-brainsci-10-00219">15</xref>], higher social awareness, and the older age of parents at childbearing [<xref ref-type="bibr" rid="B16-brainsci-10-00219">16</xref>,<xref ref-type="bibr" rid="B17-brainsci-10-00219">17</xref>]. The etiology of ASD is most likely multifactorial [<xref ref-type="bibr" rid="B11-brainsci-10-00219">11</xref>], being the result of genetic and environmental factors [<xref ref-type="bibr" rid="B6-brainsci-10-00219">6</xref>]. Hallmayer et al. indicated the predominance of environmental factors, estimating the shared environmental component to be 58% and heritability to 38%. This distribution was similar among women and men [<xref ref-type="bibr" rid="B18-brainsci-10-00219">18</xref>]. So far multiple potential risk factors for ASD have been reported in the literature, including the use of illicit drugs during pregnancy, medications, organophosphate pesticides [<xref ref-type="bibr" rid="B19-brainsci-10-00219">19</xref>], fatty acid deficiency [<xref ref-type="bibr" rid="B20-brainsci-10-00219">20</xref>], gestational diabetes, and low birth weight [<xref ref-type="bibr" rid="B11-brainsci-10-00219">11</xref>]. Despite numerous scientific studies, no genetic abnormality that would account for more than 1% of ASD has been identified yet [<xref ref-type="bibr" rid="B11-brainsci-10-00219">11</xref>]. One of the hypothesis defines ASD as a collection of many forms of a rare monogenic disorder with a different etiology [<xref ref-type="bibr" rid="B21-brainsci-10-00219">21</xref>]. Ten percent of ASD can be explained as a component of a specific genetic syndrome, e.g., Rett syndrome, fragile X syndrome or tuberous sclerosis complex [<xref ref-type="bibr" rid="B22-brainsci-10-00219">22</xref>]. Pairwise ASD concordance was 31% for dizygotic twins and 88% for monozygotic twins [<xref ref-type="bibr" rid="B23-brainsci-10-00219">23</xref>]. Hallmayer et al. reported that the proband wise concordance for male twins was 77% and for female twins was 50% for monozygotic pairs whereas for dizygotic pairs it was 31% for male twins and 36% for female twins [<xref ref-type="bibr" rid="B18-brainsci-10-00219">18</xref>].</p>
<p>Attention deficit hyperactivity disorder (ADHD) is characterized by attention disorders, impulsive behavior and hyperactivity. Oppositional-defiant disorders affect about 25% of patients and are more prevalent among school-age patients. They are characterized by stubbornness, emotional lability and argumentative behavior. About 15%–20% of children demonstrate difficulties in adapting to general social norms, manifested by a tendency to aggressive behavior, theft, and lying; 10% of children are affected by anxiety disorders and the similar percentage of children present with depression [<xref ref-type="bibr" rid="B24-brainsci-10-00219">24</xref>]. About 65% of individuals diagnosed with ADHD in childhood show the features of the disorder in adulthood [<xref ref-type="bibr" rid="B25-brainsci-10-00219">25</xref>]. A significantly higher prevalence of comorbid lifetime psychiatric disorders is reported in adults with ADHD (77.1%) compared to control probands (45.7%) [<xref ref-type="bibr" rid="B26-brainsci-10-00219">26</xref>]. The prevalence of the disorder varies depending on the studies. The American Psychiatric Association estimates the prevalence of ADHD in the Diagnostic and Statistical Manual of Mental Disorders at 5% in the pediatric population [<xref ref-type="bibr" rid="B27-brainsci-10-00219">27</xref>]. In turn, the Centers for Disease Control and Prevention found that 9.4% of children aged 2–17 years had ever received an ADHD diagnosis [<xref ref-type="bibr" rid="B28-brainsci-10-00219">28</xref>]. There is a disparity related to the diagnosis in relation to the sex. The disorder is more prevalent among boys with the ratio ranging from 3:1 to even 9:1 [<xref ref-type="bibr" rid="B24-brainsci-10-00219">24</xref>,<xref ref-type="bibr" rid="B29-brainsci-10-00219">29</xref>,<xref ref-type="bibr" rid="B30-brainsci-10-00219">30</xref>,<xref ref-type="bibr" rid="B31-brainsci-10-00219">31</xref>]. The differences can be explained by the fact that the pattern of impulsive and hyperactive disorders is more strongly expressed in boys. The lower severity of symptoms means that girls may be undiagnosed in childhood, which explains a similar frequency in the adult population [<xref ref-type="bibr" rid="B29-brainsci-10-00219">29</xref>,<xref ref-type="bibr" rid="B32-brainsci-10-00219">32</xref>]. ADHD etiology is most likely multifactorial. The literature reports potential environmental factors such as the use of stimulants or drugs in pregnancy (nicotine and alcohol), social factors (peer and family relationships) and genetic factors. The most numerous studies suggest the effects of the dopamine pathway genes: The dopamine D4 receptor gene (DRD4), the dopamine D5 receptor gene (DRD5), and the dopamine transporter gene (DAT1) [<xref ref-type="bibr" rid="B33-brainsci-10-00219">33</xref>], but more recent publications also report the potential role of the serotonin receptor family (5-HTR) [<xref ref-type="bibr" rid="B34-brainsci-10-00219">34</xref>,<xref ref-type="bibr" rid="B35-brainsci-10-00219">35</xref>] and the serotonin transporter (5HTT) [<xref ref-type="bibr" rid="B35-brainsci-10-00219">35</xref>] in the pathogenesis of ADHD. Heritability of 0.75 to 0.91 that was robust across familial relationships (siblings, twins) was observed [<xref ref-type="bibr" rid="B36-brainsci-10-00219">36</xref>].</p>
</sec>
<sec id="sec2-brainsci-10-00219">
<title>2. Melatonin in Neurodevelopmental Diseases</title>
<p>Normal MLT levels are crucial for the development of cognitive and behavioral functions [<xref ref-type="bibr" rid="B37-brainsci-10-00219">37</xref>]. In experimental studies MLT also shows antioxidant [<xref ref-type="bibr" rid="B38-brainsci-10-00219">38</xref>,<xref ref-type="bibr" rid="B39-brainsci-10-00219">39</xref>], anti-inflammatory [<xref ref-type="bibr" rid="B39-brainsci-10-00219">39</xref>], antidepressant [<xref ref-type="bibr" rid="B1-brainsci-10-00219">1</xref>], and neuroprotective effects [<xref ref-type="bibr" rid="B40-brainsci-10-00219">40</xref>]. The multidirectional effect of melatonin prompted researchers to analyze secretion in a group of patients with ASD and ADHD.</p>
<sec id="sec2dot1-brainsci-10-00219">
<title>2.1. ASD</title>
<p>There are a number of studies (<xref ref-type="table" rid="brainsci-10-00219-t001">Table 1</xref>) indicating a relationship between lowered melatonin levels and the incidence of ASD.</p>
<p>Melatonin is a compound that crosses the placenta. Maybe low maternal MLT level may be an additional risk factor for ASD in the fetus [<xref ref-type="bibr" rid="B11-brainsci-10-00219">11</xref>,<xref ref-type="bibr" rid="B41-brainsci-10-00219">41</xref>]. Decreased MLT levels were also observed in relatives of ASD patients, which may indicate the genetic background of this phenomenon [<xref ref-type="bibr" rid="B11-brainsci-10-00219">11</xref>,<xref ref-type="bibr" rid="B37-brainsci-10-00219">37</xref>,<xref ref-type="bibr" rid="B41-brainsci-10-00219">41</xref>]. The causes of decreased MLT levels can be found in the disturbances in the metabolic pathway of MLT [<xref ref-type="bibr" rid="B42-brainsci-10-00219">42</xref>]. In 40% of patients with ASD, Pagan et al. observed increased serotonin levels with a simultaneous decrease in MLT levels occurring in 51% of ASD patients. The level of the intermediate metabolite NAS was increased, on average, in 47% of patients, which may indicate the disruption of this pathway. Their analysis showed similar disorders in first-degree relatives of patients with ASD [<xref ref-type="bibr" rid="B41-brainsci-10-00219">41</xref>]. In ASD subjects, Melke et al. demonstrated that low ASMT activity, which participates in the conversion of NAS into MLT, resulted in a decreased MLT level [<xref ref-type="bibr" rid="B37-brainsci-10-00219">37</xref>]. Abnormalities in ASMT may therefore predispose to ASD. Disorders of the circadian rhythm of MLT may correlate with the severity of ASD [<xref ref-type="bibr" rid="B43-brainsci-10-00219">43</xref>,<xref ref-type="bibr" rid="B44-brainsci-10-00219">44</xref>]. The analysis showed a 4-fold higher prevalence of ASD in boys compared to girls [<xref ref-type="bibr" rid="B19-brainsci-10-00219">19</xref>,<xref ref-type="bibr" rid="B45-brainsci-10-00219">45</xref>,<xref ref-type="bibr" rid="B46-brainsci-10-00219">46</xref>] which can be explained by a higher level of melatonin (MLT) in girls than in boys, which could translate into less frequent or less severe ASD [<xref ref-type="bibr" rid="B11-brainsci-10-00219">11</xref>]. In patients with ASD, nocturnal excretion of 6-SM negatively correlated with the severity of impairment in play and verbal communication [<xref ref-type="bibr" rid="B47-brainsci-10-00219">47</xref>]. In turn, Pagan et al. did not find a significant relationship between disorders in the levels of MLT, serotonin or N-acetyl serotonin (NAS) and the severity of autistic disorders [<xref ref-type="bibr" rid="B41-brainsci-10-00219">41</xref>]. Not all children affected by ASD manifest the disturbed circadian rhythm of melatonin secretion [<xref ref-type="bibr" rid="B48-brainsci-10-00219">48</xref>]. However, patients with decreased MLT levels complained of sleep-related problems more frequently [<xref ref-type="bibr" rid="B41-brainsci-10-00219">41</xref>].</p>
</sec>
<sec id="sec2dot2-brainsci-10-00219">
<title>2.2. ADHD</title>
<p>In the group of patients with ADHD, researchers report circadian melatonin arrhythmias in the form of delayed DLMO and elevated levels of excreted 6-hydroxymelatoninsulfate (6-OH MS) relative to the control group (<xref ref-type="table" rid="brainsci-10-00219-t002">Table 2</xref>). Van der Heijden et al. examined the differences in DLMO on the basis of MLT measurements in saliva samples in children with ADHD without sleep disorders and in children with ADHD with sleep-onset insomnia (SOI). The study did not show significant differences in sleep maintenance. However, children who reported sleep disorders presented with delayed DLMO and the delayed sleep phase [<xref ref-type="bibr" rid="B53-brainsci-10-00219">53</xref>]. Van Veen MM et al., and Bijlenga D et al. also point out the co-occurring sleep problem [<xref ref-type="bibr" rid="B54-brainsci-10-00219">54</xref>,<xref ref-type="bibr" rid="B55-brainsci-10-00219">55</xref>].</p>
</sec>
</sec>
<sec id="sec3-brainsci-10-00219">
<title>3. Sleep Disorders</title>
<p>Children affected with sleep disorders can mimic the behavior of children with ADHD [<xref ref-type="bibr" rid="B58-brainsci-10-00219">58</xref>].</p>
<sec id="sec3dot1-brainsci-10-00219">
<title>3.1. ASD</title>
<p>Sleep disorders affect 50%–80% of ASD patients [<xref ref-type="bibr" rid="B19-brainsci-10-00219">19</xref>,<xref ref-type="bibr" rid="B59-brainsci-10-00219">59</xref>,<xref ref-type="bibr" rid="B60-brainsci-10-00219">60</xref>]. Many authors paid attention to the severity of ASD symptoms in children with sleep disorders [<xref ref-type="bibr" rid="B61-brainsci-10-00219">61</xref>,<xref ref-type="bibr" rid="B62-brainsci-10-00219">62</xref>,<xref ref-type="bibr" rid="B63-brainsci-10-00219">63</xref>,<xref ref-type="bibr" rid="B64-brainsci-10-00219">64</xref>,<xref ref-type="bibr" rid="B65-brainsci-10-00219">65</xref>]. Sleep disorders can present differently and take the form of difficulty falling asleep, delayed falling asleep, light sleep, frequent awakenings, shortening the sleep duration, daytime sleepiness and even insomnia [<xref ref-type="bibr" rid="B41-brainsci-10-00219">41</xref>,<xref ref-type="bibr" rid="B66-brainsci-10-00219">66</xref>,<xref ref-type="bibr" rid="B67-brainsci-10-00219">67</xref>,<xref ref-type="bibr" rid="B68-brainsci-10-00219">68</xref>]. In the Krakowiak et al. study, 529 children participated, including 303 with ASD, an analysis of parental questionnaires showed that as many as 53% of children with ASD aged 2–5 present a minimum of one sleep problem [<xref ref-type="bibr" rid="B69-brainsci-10-00219">69</xref>]. Buckley et al. observed a shortened REM sleep with an increased percentage of slow-wave sleep [<xref ref-type="bibr" rid="B66-brainsci-10-00219">66</xref>]. Wiggs et al. examined 69 children with ASD at the age of 5–16 years, the problem of insomnia affected 64% of the examined group, and the underlying was primarily behavioral problem, sleep cycle disorders and anxiety-related problems [<xref ref-type="bibr" rid="B70-brainsci-10-00219">70</xref>]. Hollway et al. found anxiety to be the strongest cause of sleep disorders in the group of ASD patients. In addition, they indicated that the quality of sleep was potentially affected by developmental regression, the age of the child and the ASD subtype—in this case sleep disorders were the most frequently reported in children with Asperger syndrome [<xref ref-type="bibr" rid="B71-brainsci-10-00219">71</xref>]. The highest percentage of sleep disorders in the group of children with ASD was presented by Liu et al. about 86%, in their work they also presented factors potentially affecting sleep disorders, such as: concomitant diseases (epilepsy, ADHD, asthma), medications taken, younger age of the child, burdened family history of sleep disorders and sleeping with parents [<xref ref-type="bibr" rid="B72-brainsci-10-00219">72</xref>]. Another problem is related to the tendency to chronic sleep disorders and a lower percentage of remission. In the study, Sivertsen et al. sleep disorders were assessed in children with ASD and in the control group when the children were 7-9 years old and 11-13 years old. The analysis showed that children with ASD were more likely to have sleep disturbances over time and were more likely to develop sleep problems relative to a healthy peer group. The estimated remission rate was 8.3% in the ASD children group compared to 52.4% in the control group [<xref ref-type="bibr" rid="B73-brainsci-10-00219">73</xref>].</p>
</sec>
<sec id="sec3dot2-brainsci-10-00219">
<title>3.2. ADHD</title>
<p>Depending on the study, a significant discrepancy is observed in the estimation of the prevalence of sleep disorders in ADHD patients. Meltzer et al. and Corkum et al. found coexisting sleep disorders in 25-50% of patients [<xref ref-type="bibr" rid="B8-brainsci-10-00219">8</xref>,<xref ref-type="bibr" rid="B74-brainsci-10-00219">74</xref>]. However, other studies reported much higher percentage reaching even as much as 70% [<xref ref-type="bibr" rid="B44-brainsci-10-00219">44</xref>,<xref ref-type="bibr" rid="B75-brainsci-10-00219">75</xref>]. The parents of control group children reported sleep disorders less frequently compared to the caregivers of ADHD patients [<xref ref-type="bibr" rid="B31-brainsci-10-00219">31</xref>]. Sleep disorders in ADHD children found in the subjective assessment seem to be more severe than those characterized by objective methods [<xref ref-type="bibr" rid="B31-brainsci-10-00219">31</xref>,<xref ref-type="bibr" rid="B74-brainsci-10-00219">74</xref>,<xref ref-type="bibr" rid="B75-brainsci-10-00219">75</xref>]. This is confirmed by Cohen-Zion et al. who used the objective methodology of actigraphy and polysomnography and did not observe significant differences in sleep architecture or continuity in children with ADHD compared to the control group [<xref ref-type="bibr" rid="B75-brainsci-10-00219">75</xref>]. Also, Lecendreux et al. did not show significant variability in sleep in ADHD boys compared to the control group [<xref ref-type="bibr" rid="B76-brainsci-10-00219">76</xref>]. Corkum et al. showed that total sleep time was not significantly different between children with ADHD and the control group [<xref ref-type="bibr" rid="B74-brainsci-10-00219">74</xref>]. In other studies on ADHD patients, their authors observed an increase in REM sleep percentage [<xref ref-type="bibr" rid="B77-brainsci-10-00219">77</xref>,<xref ref-type="bibr" rid="B78-brainsci-10-00219">78</xref>]. Golan et al. observed that the percentage of REM sleep accounted for 21.5% in the group of ADHD children and 18.9% in the control group [<xref ref-type="bibr" rid="B79-brainsci-10-00219">79</xref>]. In turn, Kirov et al. indicated the relationship between the higher percentage of REM sleep and daily functioning. However, the negative correlation was related to the intelligence quotient and the positive correlation was related to the severity of attention disorders in the group of ADHD patients [<xref ref-type="bibr" rid="B78-brainsci-10-00219">78</xref>]. The range of sleep disorders in ADHD children is wide and includes difficulties in falling asleep [<xref ref-type="bibr" rid="B8-brainsci-10-00219">8</xref>,<xref ref-type="bibr" rid="B31-brainsci-10-00219">31</xref>,<xref ref-type="bibr" rid="B80-brainsci-10-00219">80</xref>], sleep resistance [<xref ref-type="bibr" rid="B80-brainsci-10-00219">80</xref>], night awakenings [<xref ref-type="bibr" rid="B80-brainsci-10-00219">80</xref>] and higher activity during sleep [<xref ref-type="bibr" rid="B8-brainsci-10-00219">8</xref>,<xref ref-type="bibr" rid="B74-brainsci-10-00219">74</xref>,<xref ref-type="bibr" rid="B75-brainsci-10-00219">75</xref>]. For example, Golan et al. observed periodic limb movements in 15% of ADHD patients that did not occur in the control group [<xref ref-type="bibr" rid="B79-brainsci-10-00219">79</xref>]. Lopez et al. noted the coexistence of restless legs syndrome (RLS) in 33% of patients, a correlation was demonstrated between earlier ADHD manifestation and a more severe course, in the same study group the percentage of iron deficiency was found in 35.5% of patients [<xref ref-type="bibr" rid="B81-brainsci-10-00219">81</xref>]. Other disorders include restless sleep [<xref ref-type="bibr" rid="B8-brainsci-10-00219">8</xref>], difficulties in waking up in the morning [<xref ref-type="bibr" rid="B80-brainsci-10-00219">80</xref>] and drowziness during the day [<xref ref-type="bibr" rid="B8-brainsci-10-00219">8</xref>,<xref ref-type="bibr" rid="B75-brainsci-10-00219">75</xref>,<xref ref-type="bibr" rid="B76-brainsci-10-00219">76</xref>,<xref ref-type="bibr" rid="B79-brainsci-10-00219">79</xref>,<xref ref-type="bibr" rid="B80-brainsci-10-00219">80</xref>]. As a result of such disorders, worse quality of sleep [<xref ref-type="bibr" rid="B8-brainsci-10-00219">8</xref>,<xref ref-type="bibr" rid="B80-brainsci-10-00219">80</xref>], fragmented sleep [<xref ref-type="bibr" rid="B31-brainsci-10-00219">31</xref>] and shortened sleep are observed [<xref ref-type="bibr" rid="B8-brainsci-10-00219">8</xref>,<xref ref-type="bibr" rid="B31-brainsci-10-00219">31</xref>]. Furthermore, 50% of children with ADHD showed sleep-disordered breathing compared to 22% from the control group [<xref ref-type="bibr" rid="B79-brainsci-10-00219">79</xref>]. Complaints reported by the caregivers of ADHD patients also included hypersalivation, nocturnal enuresis, bruxism, and nightmares [<xref ref-type="bibr" rid="B75-brainsci-10-00219">75</xref>].</p>
<p>Treatment of ADHD includes non-pharmacological and pharmacological therapy. Drugs can be divided into two major groups, i.e., psychostimulants such as methylphenidate (MPH), which is the first-line drug, and non-psychostimulants (e.g., atomoxetine, which is a centrally acting sympathomimetic) [<xref ref-type="bibr" rid="B82-brainsci-10-00219">82</xref>]. According to some researchers, sleep disorders can be an adverse effect of stimulant drugs [<xref ref-type="bibr" rid="B24-brainsci-10-00219">24</xref>,<xref ref-type="bibr" rid="B82-brainsci-10-00219">82</xref>,<xref ref-type="bibr" rid="B83-brainsci-10-00219">83</xref>] as they can disturb the sleep pattern [<xref ref-type="bibr" rid="B84-brainsci-10-00219">84</xref>]. Schachter et al. observed that patients on MPH were affected by insomnia more frequently compared to the placebo group [<xref ref-type="bibr" rid="B85-brainsci-10-00219">85</xref>]. Galland et al. noticed the effect of MPH on sleep efficiency and observed its reduction by 6.5%, prolonged sleep onset by an average of 29 min and shortened sleep by about 1.2 h. However, the effect of MPH did not alter sleep architecture, the study compared waking time, stage 1 and 2 sleep, slow wave sleep and REM sleep [<xref ref-type="bibr" rid="B86-brainsci-10-00219">86</xref>].</p>
<p>Meltzer et al. indicated the negative effects of psychostimulants as they can worsen the quality of sleep and delay sleep onset [<xref ref-type="bibr" rid="B8-brainsci-10-00219">8</xref>]. Ironside et al. noted that stimulant medications caused an increase in motor activity after turning off the light in the child that tried to fall asleep. However, no changes in motor activity were observed when the child was in bed sleeping or when the child was active during the day [<xref ref-type="bibr" rid="B84-brainsci-10-00219">84</xref>]. Smits et al. did not show a significant influence of MPH on DLMO or sleep parameters. In the study group of children on MPH, insomnia had been observed before drug administration [<xref ref-type="bibr" rid="B87-brainsci-10-00219">87</xref>]. Pelham et al. did not observe an increase in sleep disorders in children who received MPH (5-15mg) that was administered in the afternoon [<xref ref-type="bibr" rid="B88-brainsci-10-00219">88</xref>].</p>
</sec>
</sec>
<sec id="sec4-brainsci-10-00219">
<title>4. Melatonin in the Treatment of Sleep Disorders in Children</title>
<p>The review presented above draws attention to the existing relationship between disorders of circadian melatonin secretion and sleep disorders in the group of patients with ASD or ADHD diagnosis. Some researchers suggest that treatment with exogenous melatonin may be effective due to potential causal effects by compensating for deficiencies. Below we present the effectiveness and safety of melatonin supplementation in sleep disorders in the group of pediatric patients. The analysis included publications meeting the following conditions: original papers, date of publication from 2000, the study involved children diagnosed with ASD or ADHD. The presented tables show only participants who took MLT and completed the study, excluding the control group.</p>
<sec id="sec4dot1-brainsci-10-00219">
<title>4.1. ASD</title>
<p>Treatment should be mainly based on following the sleep hygiene and behavioral interventions. When these activities do not produce satisfactory effects, physicians should consider pharmacologic treatment. Due to lower MLT concentrations in ASD patients, studies are currently conducted on the use of MLT in the treatment of sleep disorders. Goldman et al. and Veatch et al. indicated a positive effect of MLT also in the group of patients with the normal endogenous MLT profile [<xref ref-type="bibr" rid="B48-brainsci-10-00219">48</xref>,<xref ref-type="bibr" rid="B61-brainsci-10-00219">61</xref>], which suggests that the effect of exogenous MLT was not limited to correcting deficiencies. Twenty five percent of parents of children with ASD reported that the physician suggested MLT treatment for sleep disorders in their children [<xref ref-type="bibr" rid="B89-brainsci-10-00219">89</xref>]. Cortesi et al. examined treatment effectiveness of sleep disorders using MLT, cognitive-behavioral therapy, and the combination of both methods. The best effects were obtained in patients who underwent combined therapy, then in those who received MLT alone. The lowest effectiveness was observed in patients who underwent cognitive-behavioral therapy [<xref ref-type="bibr" rid="B90-brainsci-10-00219">90</xref>].</p>
<p>Short-acting and sustained-release MLT is available. Despite the lack of guidelines, sustained-release MLT is recommended for children with difficulty in maintaining sleep [<xref ref-type="bibr" rid="B6-brainsci-10-00219">6</xref>,<xref ref-type="bibr" rid="B91-brainsci-10-00219">91</xref>] whereas short-acting MLT is recommended for children with difficulty in sleep onset [<xref ref-type="bibr" rid="B3-brainsci-10-00219">3</xref>]. According to Bruni et al., MLT should be administered 30 min before bedtime at a dose of 1-3 mg if it is to act as a sleep inducer. However, if it is used as a chronobiotic, it should be given 3-4 h before sleep with the initial dose of fast release MLT (0.2-0.5 mg; the maximum dose for children—3 mg and 5 mg for adolescents) [<xref ref-type="bibr" rid="B44-brainsci-10-00219">44</xref>]. In the group of patients with ASD, different melatonin dosing regiments were used, as shown in <xref ref-type="table" rid="brainsci-10-00219-t003">Table 3</xref>.</p>
<p>Owens reported MLT doses for infants (1 mg), older children (2.5–3 mg), adolescents (5 mg) and for children with special needs (0.5–10 mg) irrespective of age [<xref ref-type="bibr" rid="B91-brainsci-10-00219">91</xref>]. Due to the fact that exogenous MLT reaches its maximum concentration one hour after administration, it is usually given 30–60 min before bedtime [<xref ref-type="bibr" rid="B6-brainsci-10-00219">6</xref>,<xref ref-type="bibr" rid="B91-brainsci-10-00219">91</xref>,<xref ref-type="bibr" rid="B92-brainsci-10-00219">92</xref>]. Since the standard dose has not been established, the need for dose modification may be necessary [<xref ref-type="bibr" rid="B98-brainsci-10-00219">98</xref>]. This is due to the fact that the effectiveness of MLT is influenced by inter-individual differences in the rate of hepatic metabolism, intestinal absorption and body weight [<xref ref-type="bibr" rid="B48-brainsci-10-00219">48</xref>]. Effective dose should be established for each patient individually [<xref ref-type="bibr" rid="B104-brainsci-10-00219">104</xref>]. In turn, Malow et al. observed that the child’s age or weight was not associated with MLT dose response [<xref ref-type="bibr" rid="B59-brainsci-10-00219">59</xref>]. According to Grigg-Damberger et al., the dose should be increased by 1 mg every 2 weeks [<xref ref-type="bibr" rid="B6-brainsci-10-00219">6</xref>]. Although therapy is generally effective, even high doses of exogenous MLT did not result in the intended effect [<xref ref-type="bibr" rid="B104-brainsci-10-00219">104</xref>] in slow MLT metabolizers due to a single nucleotide polymorphism (SNP) of CYP1A2 [<xref ref-type="bibr" rid="B105-brainsci-10-00219">105</xref>].</p>
<p>The effects of melatonin supplementation in ASD patients are shown in <xref ref-type="table" rid="brainsci-10-00219-t004">Table 4</xref>. In the Wright et al. study, the sleep pattern improved by an average of 47 min [<xref ref-type="bibr" rid="B98-brainsci-10-00219">98</xref>], in the Gringras et al. study it was about 39.6 min [<xref ref-type="bibr" rid="B100-brainsci-10-00219">100</xref>]. The researchers also measured the mean prolongation in total sleep length, in the Wright et al. study by an average of 52 min [<xref ref-type="bibr" rid="B98-brainsci-10-00219">98</xref>], in the Gingras et al. study by 57.5 minutes [<xref ref-type="bibr" rid="B100-brainsci-10-00219">100</xref>].</p>
<p>The issue of night-time awakenings remains controversial. Garstrang et al. [<xref ref-type="bibr" rid="B94-brainsci-10-00219">94</xref>], Cortesi et al. [<xref ref-type="bibr" rid="B90-brainsci-10-00219">90</xref>], Goldman et al. [<xref ref-type="bibr" rid="B48-brainsci-10-00219">48</xref>] and Maras et al. [<xref ref-type="bibr" rid="B101-brainsci-10-00219">101</xref>] postulated that their reduction after melatonin supplementation was observed whereas Wirojanan et al. [<xref ref-type="bibr" rid="B97-brainsci-10-00219">97</xref>], Wright et al. [<xref ref-type="bibr" rid="B98-brainsci-10-00219">98</xref>] and Malow B. et al. [<xref ref-type="bibr" rid="B59-brainsci-10-00219">59</xref>] did not confirm the influence of exogenous melatonin on the change of awakening frequency. Moreover, in the literature, the researchers also indicate a mild hypnotic [<xref ref-type="bibr" rid="B82-brainsci-10-00219">82</xref>,<xref ref-type="bibr" rid="B91-brainsci-10-00219">91</xref>,<xref ref-type="bibr" rid="B106-brainsci-10-00219">106</xref>], chronobiotic effect and improved daily behavior [<xref ref-type="bibr" rid="B59-brainsci-10-00219">59</xref>,<xref ref-type="bibr" rid="B107-brainsci-10-00219">107</xref>].</p>
<p>Positive effects of therapy are not achieved in all children with sleep disorders. However, the obtained results seem to be satisfactory. In a study by Malow et al., all children reported improvement in sleep disorders [<xref ref-type="bibr" rid="B59-brainsci-10-00219">59</xref>]. Jan and O’Donnell showed such improvement in 82% [<xref ref-type="bibr" rid="B108-brainsci-10-00219">108</xref>] and Ayyash et al. in 78% [<xref ref-type="bibr" rid="B104-brainsci-10-00219">104</xref>]. However, Andersen et al. showed the improvement in 60% of patients [<xref ref-type="bibr" rid="B95-brainsci-10-00219">95</xref>].</p>
</sec>
<sec id="sec4dot2-brainsci-10-00219">
<title>4.2. ADHD</title>
<p>Sleep disturbances may exacerbate the symptoms of ADHD [<xref ref-type="bibr" rid="B30-brainsci-10-00219">30</xref>,<xref ref-type="bibr" rid="B75-brainsci-10-00219">75</xref>], especially in the morning [<xref ref-type="bibr" rid="B109-brainsci-10-00219">109</xref>]. In children with ADHD sleep restriction deteriorated from subclinical levels to the clinical range of inattention [<xref ref-type="bibr" rid="B110-brainsci-10-00219">110</xref>]. Therefore, the therapy of sleep disorders is associated with the improvement in the functioning of both children with ADHD and the whole family [<xref ref-type="bibr" rid="B75-brainsci-10-00219">75</xref>,<xref ref-type="bibr" rid="B80-brainsci-10-00219">80</xref>]. Hoebert et al. showed the effects of exogenous MLT therapy in children with ADHD and chronic sleep onset insomnia (CSOI). The mean follow-up was 3.7 years. Improvement in sleep, behavior and mood was reported in 88%, 71%, and 61% of patients, respectively [<xref ref-type="bibr" rid="B111-brainsci-10-00219">111</xref>]. Van der Heijden et al. examined 105 children with ADHD and coexisting insomnia who did not receive medications. In their study MLT supplementation was used at a dose of 3 mg or 6 mg for 4 weeks. Sleep onset advanced by 26.9 ± 47.8 min in the group on MLT and delayed by 10.5 ± 37.4 min in the placebo group (<italic>p</italic> &lt; 0.0001). In the MLT group, the total time asleep also increased by 19.8 ± 61.9 min compared to the placebo group (13.6 ± 50.6 min). However, the influence of MLT on cognitive functions or problem-related behavior was not confirmed [<xref ref-type="bibr" rid="B112-brainsci-10-00219">112</xref>].</p>
<p>According to Danielson et al., pharmacological treatment was used in 62% of children with ADHD, 46.7% of children had received behavioral treatment whereas 23% of children had not received any treatment [<xref ref-type="bibr" rid="B28-brainsci-10-00219">28</xref>]. Based on these data, it is important to conduct research on the simultaneous use of stimulant medications and MLT. Weiss et al. obtained positive effects of combination therapy (sleep hygiene with MLT at a dose of 5 mg for 30 days) in children with ADHD who used stimulant medications. Insomnia was initially decreased by 16 min compared to the placebo control group [<xref ref-type="bibr" rid="B113-brainsci-10-00219">113</xref>]. TjonPian Gi et al. reported that the time of falling asleep after MLT administration varied between 15–64 min [<xref ref-type="bibr" rid="B114-brainsci-10-00219">114</xref>] in ADHD subjects on MPH and MLT at a dose of 3 mg. In turn, Masi et al. reported improved sleep in 60.8% of ADHD patients treated with MPH after MLT therapy (mean dosage 1.85 ± 0.84 mg/d) [<xref ref-type="bibr" rid="B82-brainsci-10-00219">82</xref>]. Schemes of conducted research and effects of melatonin therapy in the group of patients with ADHD are summarized in <xref ref-type="table" rid="brainsci-10-00219-t005">Table 5</xref> and <xref ref-type="table" rid="brainsci-10-00219-t006">Table 6</xref>.</p>
</sec>
</sec>
<sec id="sec5-brainsci-10-00219" sec-type="subjects">
<title>5. Safety of Exogenous Melatonin in Pediatric Patients</title>
<p>Melatonin treatment is widely regarded as safe [<xref ref-type="bibr" rid="B19-brainsci-10-00219">19</xref>,<xref ref-type="bibr" rid="B59-brainsci-10-00219">59</xref>,<xref ref-type="bibr" rid="B108-brainsci-10-00219">108</xref>] and adverse effects are rarely reported in the literature, which is the additional advantage of MLT due to the fact that there are reports on more prevalent side effects in the groups of ASD patients who received psychotropic medications compared to their peers without ASD [<xref ref-type="bibr" rid="B13-brainsci-10-00219">13</xref>]. Andersen et al. reported mild side effects, i.e., increased nocturnal enuresis, morning drowsiness. One child had worse sleep after MLT administration [<xref ref-type="bibr" rid="B95-brainsci-10-00219">95</xref>]. Other symptoms include headache and dizziness, gastric complaints (e.g., loose stools) [<xref ref-type="bibr" rid="B59-brainsci-10-00219">59</xref>,<xref ref-type="bibr" rid="B117-brainsci-10-00219">117</xref>]. While Owens paid attention to the possibility of premature puberty by the suppressing the pituitary-gonadal axis [<xref ref-type="bibr" rid="B91-brainsci-10-00219">91</xref>], Van Geijlswijk et al. did not confirm deviated pubertal development in the group of subjects on MLT (mean period of administration was 3.1 years) with the mean dose of 2.69 mg compared to the age and sex-matched control group [<xref ref-type="bibr" rid="B118-brainsci-10-00219">118</xref>]. Malow et al. noted the severity of fatigue during the dose increase, which resolved after repeated reduction of supplementation [<xref ref-type="bibr" rid="B103-brainsci-10-00219">103</xref>]. Babineau et al. in their study indicated the safety and effectiveness of short-term MLT therapy in children [<xref ref-type="bibr" rid="B119-brainsci-10-00219">119</xref>].</p>
<p>Long-term studies on melatonin supplementation were conducted by Malow et al. for 104 weeks [<xref ref-type="bibr" rid="B103-brainsci-10-00219">103</xref>], Hoebert et al. for a diameter of 3.66 ± 0.12 years [<xref ref-type="bibr" rid="B111-brainsci-10-00219">111</xref>], Van Geijlswijk et al. for one to 4.6 years [<xref ref-type="bibr" rid="B118-brainsci-10-00219">118</xref>], Carr et al. for an average of 4.3 years [<xref ref-type="bibr" rid="B120-brainsci-10-00219">120</xref>], and Jan and O’Donnell for a period of several weeks up to 4 years [<xref ref-type="bibr" rid="B108-brainsci-10-00219">108</xref>]. Safety of MLT in children was confirmed by these studies. In the research by Hoebert et al. [<xref ref-type="bibr" rid="B111-brainsci-10-00219">111</xref>] and TjonPian Gi et al. [<xref ref-type="bibr" rid="B114-brainsci-10-00219">114</xref>] it was noted that discontinuation of exogenous MLT was associated with recurrent sleep disorders and further supplementation was required. In the study of Malow et al. intermittently long-term therapy resulted in a deterioration in sleep, but the patients’ condition remained better than it was at baseline [<xref ref-type="bibr" rid="B103-brainsci-10-00219">103</xref>]. Carr et al. compared MLT doses in 33 patients without previous exogenous MLT therapy in whom the treatment lasted from 9 months to 3.8 years (mean 2.5 years) with the doses in 11 patients previously on MLT from 5 months to 9.6 years (mean 5.1 years). The final dosage of exogenous MLT was not statistically significantly different in both subgroups, suggesting that tolerance in MLT patients did not develop over long-term use [<xref ref-type="bibr" rid="B120-brainsci-10-00219">120</xref>]. The same conclusions were presented by Jan and O’Donnell [<xref ref-type="bibr" rid="B108-brainsci-10-00219">108</xref>]. The effects of MLT supplementation after the first weeks were comparable with those observed after 3 months [<xref ref-type="bibr" rid="B114-brainsci-10-00219">114</xref>]. Masi et al. and Weiss et al. found that combination therapy of MPH and MLT was effective and safe [<xref ref-type="bibr" rid="B82-brainsci-10-00219">82</xref>,<xref ref-type="bibr" rid="B113-brainsci-10-00219">113</xref>].</p>
</sec>
<sec id="sec6-brainsci-10-00219" sec-type="discussion">
<title>6. Discussion</title>
<p>This review indicates the significance of sleep disorders in the pediatric group, especially in children with neurodevelopmental disorders.</p>
<p>It remains unclear whether sleep problems are part of the clinical picture of ASD and ADHD or are provoked by anxiety or behavioral disorders. The authors point out circadian arrhythmias in this group of patients. However, it is certain that poor sleep quality translates into poorer functioning, not only for the patient but also for their carers. It should be remembered that the first action of a clinician should be to look for the cause of the problem and convince the patient and his family to observe proper sleep hygiene and only then pharmacotherapy.</p>
<p>Recommendations for the treatment of sleep problems in children with neurodevelopmental disorders involves behavioral interventions aimed at maintaining the patient’s activity during the day, together with the reduction and control of stimuli during the night period. The melatonin treatment and adherence to sleep hygiene, collectively with planning regular bedtime and waking up time, and avoiding daytime naps are important. Melatonin is one of the most commonly used agents for sleep disorders in the group of pediatric patients [<xref ref-type="bibr" rid="B98-brainsci-10-00219">98</xref>].</p>
<p>The presented data testify to the beneficial effect of melatonin supplementation. The authors seem to agree that exogenous melatonin improves sleep delay as well as extends overall sleep duration in the group of patients with ASD and ADHD. British Society of Psychopharmacology in 2018 [<xref ref-type="bibr" rid="B121-brainsci-10-00219">121</xref>] based on Rossignol and Frye data from 2011 (evidence level Ia) [<xref ref-type="bibr" rid="B107-brainsci-10-00219">107</xref>] and Cortesi et al. from 2012 (evidence level Ib) [<xref ref-type="bibr" rid="B90-brainsci-10-00219">90</xref>] recommends the use of melatonin in children with ASD. Data on the effects of melatonin on behavior are less numerous. In the group of ASD patients, researchers agree that melatonin has a positive effect on behavior. Van der Heijden et al. and Mohammadi et al. they did not find a beneficial effect of melatonin supplementation on the behavior of patients with ADHD [<xref ref-type="bibr" rid="B112-brainsci-10-00219">112</xref>,<xref ref-type="bibr" rid="B115-brainsci-10-00219">115</xref>], interestingly, Hoebert et al. described an improvement in patient behavior [<xref ref-type="bibr" rid="B111-brainsci-10-00219">111</xref>]. These differences may be related to the duration of therapy because Hoebert et al., conducted the longest observation of patients—an average of 3.66 ± 0.12 year [<xref ref-type="bibr" rid="B111-brainsci-10-00219">111</xref>]. The obtained sleep improvement in the patient also improves the quality of life of the caregiver and the whole family of the patient.</p>
<p>Of note, despite the widespread use, MLT is not a medication but an over-the-counter dietary supplement. As a result, it is not subject to such strict monitoring of adverse effects compared to prescription drugs. In the above studies, adverse reactions were absent or rare. MLT is considered safe and well-tolerated. High availability and a low price of MLT are its advantages. The biggest benefit of melatonin is its high effectiveness. Discontinuation of MLT treatment is often associated with recurrent sleep disorders.</p>
<p>The review presented extensively presents the protocols used for melatonin supplementation, which may facilitate the work of clinicians because there has not been a uniform dosage standard to date.</p>
</sec>
<sec id="sec7-brainsci-10-00219">
<title>7. Limitations</title>
<p>The review presented extensively presents the protocols used for melatonic supplementation, which may facilitate the work of clinicians because there has not been a uniform dosage standard to date.</p>
<p>The review has several limitations:<list list-type="simple"><list-item><label>-</label><p>This is not a systematic review carried out in accordance with the PRISMA guidelines;</p></list-item><list-item><label>-</label><p>research groups are not limited to patients with ASD and ADHD;</p></list-item><list-item><label>-</label><p>no homogeneous test report;</p></list-item><list-item><label>-</label><p>the use of various melatonin preparations in studies;</p></list-item><list-item><label>-</label><p>depending on the publication, various parameters (assessment of sleep disorders, assessment of behavior) were assessed using various methods (objective - actigraphy, polysomnography and subjective - sleep diaries, questionnaires); and</p></list-item><list-item><label>-</label><p>lack of careful monitoring also of light side effects.</p></list-item></list></p>
</sec>
<sec id="sec8-brainsci-10-00219" sec-type="conclusions">
<title>8. Conclusions</title>
<p>Despite the limitations, our review confirms the efficacy and safety of melatonin in the treatment of sleep disorders in the group of pediatric patients. We noticed a small amount of work on the effect of melatonin on behavior and the need to design a large long-term study using both subjective and objective methods to assess the effectiveness of melatonin.</p>
</sec>
</body>
<back>
<notes>
<title>Author Contributions</title>
<p>Conceptualization, B.R.-M., J.P.; Methodology, B.R.-M., J.P.; Formal Analysis, B.R.-M.; Data Curation, B.R.-M.; Writing—Original Draft Preparation, B.R.-M., J.P.; Writing—Review and Editing, J.P.; Visualization, B.R.-M., J.P.; Supervision, J.P.; Project Administration, J.P.; All authors have read and agreed to the published version of the manuscript.</p>
</notes>
<notes>
<title>Funding</title>
<p>This research received no external funding.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflicts of interest.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-brainsci-10-00219">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dmitrzak-Weglarz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Reszka</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Pathophysiology of Depression: Molecular regulation of melatonin homeostasis—Current status</article-title>
<source/>Neuropsychobiology
          <year>2017</year>
<volume>76</volume>
<fpage>117</fpage>
<lpage>129</lpage>
<pub-id pub-id-type="doi">10.1159/000489470</pub-id>
<pub-id pub-id-type="pmid">29898451</pub-id>
</element-citation>
</ref>
<ref id="B2-brainsci-10-00219">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dahl</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>Pelham</surname>
<given-names>W.E.</given-names>
</name>
<name>
<surname>Wierson</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The role of sleep disturbances in attention deficit disorder symptoms: A case study</article-title>
<source/>J. Pediatr. Psychol.
          <year>1991</year>
<volume>16</volume>
<fpage>229</fpage>
<lpage>239</lpage>
<pub-id pub-id-type="doi">10.1093/jpepsy/16.2.229</pub-id>
<pub-id pub-id-type="pmid">2061790</pub-id>
</element-citation>
</ref>
<ref id="B3-brainsci-10-00219">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cummings</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Melatonin for the management of sleep disorders in children and adolescents</article-title>
<source/>Paediatr. Child Health
          <year>2012</year>
<volume>17</volume>
<fpage>331</fpage>
<lpage>336</lpage>
<pub-id pub-id-type="pmid">23730172</pub-id>
</element-citation>
</ref>
<ref id="B4-brainsci-10-00219">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fricke-Oerkermann</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Plück</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Schredl</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Heinz</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mitschke</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wiater</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lehmkuhl</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Prevalence and course of sleep problems in childhood</article-title>
<source/>Sleep
          <year>2007</year>
<volume>30</volume>
<fpage>1371</fpage>
<lpage>1377</lpage>
<pub-id pub-id-type="doi">10.1093/sleep/30.10.1371</pub-id>
<pub-id pub-id-type="pmid">17969471</pub-id>
</element-citation>
</ref>
<ref id="B5-brainsci-10-00219">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Couturier</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Speechley</surname>
<given-names>K.N.</given-names>
</name>
<name>
<surname>Steele</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Norman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Stringer</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Nicolson</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Parental perception of sleep problems in children of normal intelligence with pervasive developmental disorders: Prevalence, severity, and pattern</article-title>
<source/>J. Am. Acad. Child Adolesc. Psychiatry
          <year>2005</year>
<volume>44</volume>
<fpage>815</fpage>
<lpage>822</lpage>
<pub-id pub-id-type="doi">10.1097/01.chi.0000166377.22651.87</pub-id>
<pub-id pub-id-type="pmid">16034284</pub-id>
</element-citation>
</ref>
<ref id="B6-brainsci-10-00219">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grigg-Damberger</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ralls</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Treatment strategies for complex behavioral insomnia in children with neurodevelopmental disorders</article-title>
<source/>Curr. Opin. Pulm. Med.
          <year>2013</year>
<volume>19</volume>
<fpage>616</fpage>
<lpage>625</lpage>
<pub-id pub-id-type="doi">10.1097/MCP.0b013e328365ab89</pub-id>
<pub-id pub-id-type="pmid">24055857</pub-id>
</element-citation>
</ref>
<ref id="B7-brainsci-10-00219">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Damiani</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Sweet</surname>
<given-names>B.V.</given-names>
</name>
<name>
<surname>Sohoni</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Melatonin: An option for managing sleep disorders in children with autism spectrum disorder</article-title>
<source/>Am. J. Health Syst. Pharm.
          <year>2014</year>
<volume>71</volume>
<fpage>95</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="doi">10.2146/ajhp130215</pub-id>
<pub-id pub-id-type="pmid">24375600</pub-id>
</element-citation>
</ref>
<ref id="B8-brainsci-10-00219">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meltzer</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Mindell</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Sleep and Sleep Disorders in Children and Adolescents</article-title>
<source/>Psychiatr. Clin. N. Am.
          <year>2006</year>
<volume>29</volume>
<fpage>1059</fpage>
<lpage>1076</lpage>
<pub-id pub-id-type="doi">10.1016/j.psc.2006.08.004</pub-id>
</element-citation>
</ref>
<ref id="B9-brainsci-10-00219">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kado</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sanada</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Oono</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ogino</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nouno</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Children with autism spectrum disorder comorbid with attention-deficit/hyperactivity disorder examined by the Wisconsin card sorting test: Analysis by age-related differences</article-title>
<source/>Brain Dev.
          <year>2020</year>
<volume>42</volume>
<fpage>113</fpage>
<lpage>120</lpage>
<pub-id pub-id-type="doi">10.1016/j.braindev.2019.07.011</pub-id>
<pub-id pub-id-type="pmid">31785985</pub-id>
</element-citation>
</ref>
<ref id="B10-brainsci-10-00219">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castellanos</surname>
<given-names>F.X.</given-names>
</name>
<name>
<surname>Sonuga-Barke</surname>
<given-names>E.J.S.</given-names>
</name>
<name>
<surname>Scheres</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Di Martino</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hyde</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Walters</surname>
<given-names>J.R.</given-names>
</name>
</person-group>
<article-title>Varieties of Attention-Deficit/Hyperactivity Disorder-Related Intra-Individual Variability</article-title>
<source/>Biol. Psychiatry
          <year>2005</year>
<volume>57</volume>
<fpage>1416</fpage>
<lpage>1423</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2004.12.005</pub-id>
<pub-id pub-id-type="pmid">15950016</pub-id>
</element-citation>
</ref>
<ref id="B11-brainsci-10-00219">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braam</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Ehrhart</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Maas</surname>
<given-names>A.P.H.M.</given-names>
</name>
<name>
<surname>Smits</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Curfs</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Low maternal melatonin level increases autism spectrum disorder risk in children</article-title>
<source/>Res. Dev. Disabil.
          <year>2018</year>
<volume>82</volume>
<fpage>79</fpage>
<lpage>89</lpage>
<pub-id pub-id-type="doi">10.1016/j.ridd.2018.02.017</pub-id>
<pub-id pub-id-type="pmid">29501372</pub-id>
</element-citation>
</ref>
<ref id="B12-brainsci-10-00219">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldman</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Alder</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Burgess</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Corbett</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Hundley</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wofford</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Fawkes</surname>
<given-names>D.B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Laudenslager</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Malow</surname>
<given-names>B.A.</given-names>
</name>
</person-group>
<article-title>Characterizing sleep in adolescents and adults with autism spectrum disorders</article-title>
<source/>J. Autism. Dev. Disord.
          <year>2017</year>
<volume>47</volume>
<fpage>1682</fpage>
<lpage>1695</lpage>
<pub-id pub-id-type="doi">10.1007/s10803-017-3089-1</pub-id>
<pub-id pub-id-type="pmid">28286917</pub-id>
</element-citation>
</ref>
<ref id="B13-brainsci-10-00219">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ji</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Findling</surname>
<given-names>R.L.</given-names>
</name>
</person-group>
<article-title>An update on pharmacotherapy for autism spectrum disorder in children and adolescents</article-title>
<source/>Curr. Opin. Psychiatry
          <year>2015</year>
<volume>28</volume>
<fpage>91</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="doi">10.1097/YCO.0000000000000132</pub-id>
<pub-id pub-id-type="pmid">25602248</pub-id>
</element-citation>
</ref>
<ref id="B14-brainsci-10-00219">
<label>14.</label>
<element-citation publication-type="gov">
<article-title>Centers for Disease Control and Prevention</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/ncbddd/autism/data.html">https://www.cdc.gov/ncbddd/autism/data.html</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2020-03-08">(accessed on 8 March 2020)</date-in-citation>
</element-citation>
</ref>
<ref id="B15-brainsci-10-00219">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>King</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bearman</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Diagnostic change and the increased prevalence of autism</article-title>
<source/>Int. J. Epidemiol.
          <year>2009</year>
<volume>38</volume>
<fpage>1224</fpage>
<lpage>1234</lpage>
<pub-id pub-id-type="doi">10.1093/ije/dyp261</pub-id>
<pub-id pub-id-type="pmid">19737791</pub-id>
</element-citation>
</ref>
<ref id="B16-brainsci-10-00219">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Croen</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Najjar</surname>
<given-names>D.V.</given-names>
</name>
<name>
<surname>Fireman</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Grether</surname>
<given-names>J.K.</given-names>
</name>
</person-group>
<article-title>Maternal and paternal age and risk of autism spectrum disorders</article-title>
<source/>Arch. Pediatr. Adolesc. Med.
          <year>2007</year>
<volume>161</volume>
<fpage>334</fpage>
<pub-id pub-id-type="doi">10.1001/archpedi.161.4.334</pub-id>
<pub-id pub-id-type="pmid">17404129</pub-id>
</element-citation>
</ref>
<ref id="B17-brainsci-10-00219">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parner</surname>
<given-names>E.T.</given-names>
</name>
<name>
<surname>Baron-Cohen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lauritsen</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Jørgensen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schieve</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Yeargin Allsopp</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Obel</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Parental age and autism spectrum disorders</article-title>
<source/>Ann. Epidemiol.
          <year>2012</year>
<volume>22</volume>
<fpage>143</fpage>
<lpage>150</lpage>
<pub-id pub-id-type="doi">10.1016/j.annepidem.2011.12.006</pub-id>
<pub-id pub-id-type="pmid">22277122</pub-id>
</element-citation>
</ref>
<ref id="B18-brainsci-10-00219">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hallmayer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cleveland</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Torigoe</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fedele</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic heritability and shared environmental factors among twin pairs with autism</article-title>
<source/>Arch. Gen. Psychiatry
          <year>2011</year>
<volume>68</volume>
<fpage>1095</fpage>
<lpage>1102</lpage>
<pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2011.76</pub-id>
<pub-id pub-id-type="pmid">21727249</pub-id>
</element-citation>
</ref>
<ref id="B19-brainsci-10-00219">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klein</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kemper</surname>
<given-names>K.J.</given-names>
</name>
</person-group>
<article-title>Integrative approaches to caring for children with autism</article-title>
<source/>Curr. Probl. Pediatr. Adolesc. Health Care
          <year>2016</year>
<volume>46</volume>
<fpage>195</fpage>
<lpage>201</lpage>
<pub-id pub-id-type="doi">10.1016/j.cppeds.2015.12.004</pub-id>
<pub-id pub-id-type="pmid">26776326</pub-id>
</element-citation>
</ref>
<ref id="B20-brainsci-10-00219">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bell</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>MacDonald</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>MacKinlay</surname>
<given-names>E.E.</given-names>
</name>
<name>
<surname>Dick</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Cheseldine</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Boyle</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>O’Hare</surname>
<given-names>A.E.</given-names>
</name>
</person-group>
<article-title>The fatty acid compositions of erythrocyte and plasma polar lipids in children with autism, developmental delay or typically developing controls and the effect of fish oil intake</article-title>
<source/>Br. J. Nutr.
          <year>2010</year>
<volume>103</volume>
<fpage>1160</fpage>
<lpage>1167</lpage>
<pub-id pub-id-type="doi">10.1017/S0007114509992881</pub-id>
<pub-id pub-id-type="pmid">19995470</pub-id>
</element-citation>
</ref>
<ref id="B21-brainsci-10-00219">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Takumi</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Genomic and genetic aspects of autism spectrum disorder</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <year>2014</year>
<volume>452</volume>
<fpage>244</fpage>
<lpage>253</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2014.08.108</pub-id>
<pub-id pub-id-type="pmid">25173933</pub-id>
</element-citation>
</ref>
<ref id="B22-brainsci-10-00219">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muhle</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Trentacoste</surname>
<given-names>S.V.</given-names>
</name>
<name>
<surname>Rapin</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>The genetics of autism</article-title>
<source/>Pediatrics
          <year>2004</year>
<volume>113</volume>
<fpage>e472</fpage>
<lpage>e486</lpage>
<pub-id pub-id-type="doi">10.1542/peds.113.5.e472</pub-id>
<pub-id pub-id-type="pmid">15121991</pub-id>
</element-citation>
</ref>
<ref id="B23-brainsci-10-00219">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosenberg</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>Law</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Yenokyan</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>McGready</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kaufmann</surname>
<given-names>W.E.</given-names>
</name>
<name>
<surname>Law</surname>
<given-names>P.A.</given-names>
</name>
</person-group>
<article-title>Characteristics and concordance of autism spectrum disorders among 277 twin pairs</article-title>
<source/>Arch. Pediatr. Adolesc. Med.
          <year>2009</year>
<volume>163</volume>
<fpage>907</fpage>
<lpage>914</lpage>
<pub-id pub-id-type="doi">10.1001/archpediatrics.2009.98</pub-id>
<pub-id pub-id-type="pmid">19805709</pub-id>
</element-citation>
</ref>
<ref id="B24-brainsci-10-00219">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schachar</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Attention deficit hyperactivity disorder in children, adolescents, and adults</article-title>
<source/>Contin. Lifelong Learn. Neurol.
          <year>2009</year>
<volume>15</volume>
<fpage>78</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="doi">10.1212/01.CON.0000348879.09070.21</pub-id>
</element-citation>
</ref>
<ref id="B25-brainsci-10-00219">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faraone</surname>
<given-names>S.V.</given-names>
</name>
<name>
<surname>Biederman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mick</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>The age-dependent decline of attention deficit hyperactivity disorder: A meta-analysis of follow-up studies</article-title>
<source/>Psychol. Med.
          <year>2006</year>
<volume>36</volume>
<fpage>159</fpage>
<lpage>165</lpage>
<pub-id pub-id-type="doi">10.1017/S003329170500471X</pub-id>
<pub-id pub-id-type="pmid">16420712</pub-id>
</element-citation>
</ref>
<ref id="B26-brainsci-10-00219">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sobanski</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Brüggemann</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Alm</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kern</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Deschner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schubert</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Philipsen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rietschel</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Psychiatric comorbidity and functional impairment in a clinically referred sample of adults with attention-deficit/hyperactivity disorder (ADHD)</article-title>
<source/>Eur. Arch. Psychiatry Clin. Neurosci.
          <year>2007</year>
<volume>257</volume>
<fpage>371</fpage>
<lpage>377</lpage>
<pub-id pub-id-type="doi">10.1007/s00406-007-0712-8</pub-id>
<pub-id pub-id-type="pmid">17902010</pub-id>
</element-citation>
</ref>
<ref id="B27-brainsci-10-00219">
<label>27.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<collab>American Psychiatric Association</collab>
</person-group>
<source/>Diagnostic and Statistical Manual of Mental Disorders
          <edition>5th ed.</edition>
<comment>DSM-5</comment>
<publisher-name>American Psychiatric Association</publisher-name>
<publisher-loc>Washington, DC, USA</publisher-loc>
<year>2013</year>
</element-citation>
</ref>
<ref id="B28-brainsci-10-00219">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Danielson</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Bitsko</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Ghandour</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Holbrook</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Kogan</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Blumberg</surname>
<given-names>S.J.</given-names>
</name>
</person-group>
<article-title>Prevalence of parent-reported ADHD diagnosis and associated treatment among U.S. children and adolescents, 2016</article-title>
<source/>J. Clin. Child Adolesc. Psychol.
          <year>2018</year>
<volume>47</volume>
<fpage>199</fpage>
<lpage>212</lpage>
<pub-id pub-id-type="doi">10.1080/15374416.2017.1417860</pub-id>
<pub-id pub-id-type="pmid">29363986</pub-id>
</element-citation>
</ref>
<ref id="B29-brainsci-10-00219">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akutagava-Martins</surname>
<given-names>G.C.</given-names>
</name>
<name>
<surname>Salatino-Oliveira</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kieling</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Rohde</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Hutz</surname>
<given-names>M.H.</given-names>
</name>
</person-group>
<article-title>Genetics of attention-deficit/hyperactivity disorder: Current findings and future directions</article-title>
<source/>Expert Rev. Neurother.
          <year>2013</year>
<volume>13</volume>
<fpage>435</fpage>
<lpage>445</lpage>
<pub-id pub-id-type="doi">10.1586/ern.13.30</pub-id>
<pub-id pub-id-type="pmid">23545057</pub-id>
</element-citation>
</ref>
<ref id="B30-brainsci-10-00219">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brand</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kirov</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Sleep and its importance in adolescence and in common adolescent somatic and psychiatric conditions</article-title>
<source/>Int. J. Gen. Med.
          <year>2011</year>
<volume>4</volume>
<fpage>425</fpage>
<lpage>442</lpage>
<pub-id pub-id-type="doi">10.2147/IJGM.S11557</pub-id>
<pub-id pub-id-type="pmid">21731894</pub-id>
</element-citation>
</ref>
<ref id="B31-brainsci-10-00219">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corkum</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Davidson</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>MacPherson</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>A Framework for the assessment and treatment of sleep problems in children with attention-deficit/hyperactivity disorder</article-title>
<source/>Pediatr. Clin. N. Am.
          <year>2011</year>
<volume>58</volume>
<fpage>667</fpage>
<lpage>683</lpage>
<pub-id pub-id-type="doi">10.1016/j.pcl.2011.03.004</pub-id>
</element-citation>
</ref>
<ref id="B32-brainsci-10-00219">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayashi</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Saga</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Arai</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Igarashi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tokumasu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ota</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Takashio</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Iwanami</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Clinical Characteristics of Women with ADHD in Japan</article-title>
<source/>Neuropsychiatr. Dis. Treat.
          <year>2019</year>
<volume>15</volume>
<fpage>3367</fpage>
<lpage>3374</lpage>
<pub-id pub-id-type="doi">10.2147/NDT.S232565</pub-id>
<pub-id pub-id-type="pmid">31824160</pub-id>
</element-citation>
</ref>
<ref id="B33-brainsci-10-00219">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Remschmidt</surname>
<given-names>H.</given-names>
</name>
<collab>Global ADHD Working Group</collab>
</person-group>
<article-title>Global consensus on ADHD/HKD</article-title>
<source/>Eur. Child Adolesc. Psychiatry
          <year>2005</year>
<volume>14</volume>
<fpage>127</fpage>
<lpage>137</lpage>
<pub-id pub-id-type="doi">10.1007/s00787-005-0439-x</pub-id>
<pub-id pub-id-type="pmid">15959658</pub-id>
</element-citation>
</ref>
<ref id="B34-brainsci-10-00219">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hou</surname>
<given-names>Y.W.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Association of Serotonin Receptors with Attention Deficit Hyperactivity Disorder: A Systematic Review and Meta-analysis</article-title>
<source/>Curr. Med. Sci.
          <year>2018</year>
<volume>38</volume>
<fpage>538</fpage>
<lpage>551</lpage>
<pub-id pub-id-type="doi">10.1007/s11596-018-1912-3</pub-id>
<pub-id pub-id-type="pmid">30074224</pub-id>
</element-citation>
</ref>
<ref id="B35-brainsci-10-00219">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gizer</surname>
<given-names>I.R.</given-names>
</name>
<name>
<surname>Ficks</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Waldman</surname>
<given-names>I.D.</given-names>
</name>
</person-group>
<article-title>Candidate gene studies of ADHD: A meta-analytic review</article-title>
<source/>Hum. Genet.
          <year>2009</year>
<volume>126</volume>
<fpage>51</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="doi">10.1007/s00439-009-0694-x</pub-id>
<pub-id pub-id-type="pmid">19506906</pub-id>
</element-citation>
</ref>
<ref id="B36-brainsci-10-00219">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levy</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hay</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>McStephen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Waldman</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Attention-deficit hyperactivity disorder: A category or a continuum? Genetic analysis of a large-scale twin study</article-title>
<source/>J. Am. Acad. Child Adolesc. Psychiatry
          <year>1997</year>
<volume>36</volume>
<fpage>737</fpage>
<lpage>744</lpage>
<pub-id pub-id-type="doi">10.1097/00004583-199706000-00009</pub-id>
<pub-id pub-id-type="pmid">9183127</pub-id>
</element-citation>
</ref>
<ref id="B37-brainsci-10-00219">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Melke</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Goubran Botros</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chaste</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Betancur</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nygren</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Anckarsäter</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Rastam</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ståhlberg</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Gillberg</surname>
<given-names>I.C.</given-names>
</name>
<name>
<surname>Delorme</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Abnormal melatonin synthesis in autism spectrum disorders</article-title>
<source/>Mol. Psychiatry
          <year>2008</year>
<volume>13</volume>
<fpage>90</fpage>
<lpage>98</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4002016</pub-id>
<pub-id pub-id-type="pmid">17505466</pub-id>
</element-citation>
</ref>
<ref id="B38-brainsci-10-00219">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reiter</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>The pineal gland and melatonin in relation to aging: A summary of the theories and of the data</article-title>
<source/>Exp. Gerontol.
          <year>1995</year>
<volume>30</volume>
<fpage>199</fpage>
<lpage>212</lpage>
<pub-id pub-id-type="doi">10.1016/0531-5565(94)00045-5</pub-id>
<pub-id pub-id-type="pmid">7556503</pub-id>
</element-citation>
</ref>
<ref id="B39-brainsci-10-00219">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maitra</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bhattacharya</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bhattacharya</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Melatonin and its anti-glioma functions: A comprehensive review</article-title>
<source/>Rev. Neurosci.
          <year>2019</year>
<volume>30</volume>
<fpage>527</fpage>
<lpage>541</lpage>
<pub-id pub-id-type="doi">10.1515/revneuro-2018-0041</pub-id>
<pub-id pub-id-type="pmid">30645197</pub-id>
</element-citation>
</ref>
<ref id="B40-brainsci-10-00219">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sinha</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Degaonkar</surname>
<given-names>M.N.</given-names>
</name>
<name>
<surname>Jagannathan</surname>
<given-names>N.R.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>Y.K.</given-names>
</name>
</person-group>
<article-title>Effect of melatonin on ischemia reperfusion injury induced by middle cerebral artery occlusion in rats</article-title>
<source/>Eur. J. Pharmacol.
          <year>2001</year>
<volume>428</volume>
<fpage>185</fpage>
<lpage>192</lpage>
<pub-id pub-id-type="doi">10.1016/S0014-2999(01)01253-5</pub-id>
<pub-id pub-id-type="pmid">11675035</pub-id>
</element-citation>
</ref>
<ref id="B41-brainsci-10-00219">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pagan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Delorme</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Callebert</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Goubran-Botros</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Amsellem</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Drouot</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Boudebesse</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Le Dudal</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ngo-Nguyen</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Laouamri</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The serotonin-N-acetylserotonin–melatonin pathway as a biomarker for autism spectrum disorders</article-title>
<source/>Transl. Psychiatry
          <year>2014</year>
<volume>4</volume>
<fpage>e479</fpage>
<pub-id pub-id-type="doi">10.1038/tp.2014.120</pub-id>
<pub-id pub-id-type="pmid">25386956</pub-id>
</element-citation>
</ref>
<ref id="B42-brainsci-10-00219">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Ansary</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Al-Ghamdi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bhat</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Al-daihan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Al-Ayadhi</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Potency of pre–post treatment of coenzyme Q10 and melatonin supplement in ameliorating the impaired fatty acid profile in rodent model of autism</article-title>
<source/>Food Nutr. Res.
          <year>2016</year>
<volume>60</volume>
<fpage>28127</fpage>
<pub-id pub-id-type="doi">10.3402/fnr.v60.28127</pub-id>
<pub-id pub-id-type="pmid">26945230</pub-id>
</element-citation>
</ref>
<ref id="B43-brainsci-10-00219">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tordjman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Bellissant</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Botbol</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Charbuy</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Camus</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Graignic</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kermarrec</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fougerou</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Day and nighttime excretion of 6-sulphatoxymelatonin in adolescents and young adults with autistic disorder</article-title>
<source/>Psychoneuroendocrinology
          <year>2012</year>
<volume>37</volume>
<fpage>1990</fpage>
<lpage>1997</lpage>
<pub-id pub-id-type="doi">10.1016/j.psyneuen.2012.04.013</pub-id>
<pub-id pub-id-type="pmid">22613035</pub-id>
</element-citation>
</ref>
<ref id="B44-brainsci-10-00219">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruni</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Alonso-Alconada</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Besag</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Biran</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Braam</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Cortese</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Moavero</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Parisi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Smits</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Van der Heijden</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Current role of melatonin in pediatric neurology: Clinical recommendations</article-title>
<source/>Eur. J. Paediatr. Neurol.
          <year>2015</year>
<volume>19</volume>
<fpage>122</fpage>
<lpage>133</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejpn.2014.12.007</pub-id>
<pub-id pub-id-type="pmid">25553845</pub-id>
</element-citation>
</ref>
<ref id="B45-brainsci-10-00219">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baio</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wiggins</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Christensen</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Maenner</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Daniels</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Kurzius-Spencer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zahorodny</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Robinson Rosenberg</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>White</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prevalence of autism spectrum disorder among children aged 8 years—Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2014</article-title>
<source/>MMWR Surveill Summ.
          <year>2018</year>
<volume>67</volume>
<fpage>1</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="doi">10.15585/mmwr.ss6706a1</pub-id>
<pub-id pub-id-type="pmid">29701730</pub-id>
</element-citation>
</ref>
<ref id="B46-brainsci-10-00219">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fombonne</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Epidemiological surveys of autism and other pervasive developmental disorders: An update</article-title>
<source/>J. Autism. Dev. Disord.
          <year>2003</year>
<volume>33</volume>
<fpage>365</fpage>
<lpage>382</lpage>
<pub-id pub-id-type="doi">10.1023/A:1025054610557</pub-id>
<pub-id pub-id-type="pmid">12959416</pub-id>
</element-citation>
</ref>
<ref id="B47-brainsci-10-00219">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tordjman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Pichard</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Charbuy</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Touitou</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Nocturnal excretion of 6-sulphatoxymelatonin in children and adolescents with autistic disorder</article-title>
<source/>Biol. Psychiatry
          <year>2005</year>
<volume>57</volume>
<fpage>134</fpage>
<lpage>138</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2004.11.003</pub-id>
<pub-id pub-id-type="pmid">15652871</pub-id>
</element-citation>
</ref>
<ref id="B48-brainsci-10-00219">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldman</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Adkins</surname>
<given-names>K.W.</given-names>
</name>
<name>
<surname>Calcutt</surname>
<given-names>M.W.</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Goodpaster</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Burgess</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Hachey</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Malow</surname>
<given-names>B.A.</given-names>
</name>
</person-group>
<article-title>Melatonin in Children with Autism Spectrum Disorders: Endogenous and pharmacokinetic profiles in relation to sleep</article-title>
<source/>J. Autism. Dev. Disord.
          <year>2014</year>
<volume>44</volume>
<fpage>2525</fpage>
<lpage>2535</lpage>
<pub-id pub-id-type="doi">10.1007/s10803-014-2123-9</pub-id>
<pub-id pub-id-type="pmid">24752680</pub-id>
</element-citation>
</ref>
<ref id="B49-brainsci-10-00219">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nir</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Meir</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zilber</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Knobler</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hadjez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lerner</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Brief report: Circadian melatonin, thyroid-stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism</article-title>
<source/>J. Autism. Dev. Disord.
          <year>1995</year>
<volume>25</volume>
<fpage>641</fpage>
<lpage>654</lpage>
<pub-id pub-id-type="doi">10.1007/BF02178193</pub-id>
<pub-id pub-id-type="pmid">8720032</pub-id>
</element-citation>
</ref>
<ref id="B50-brainsci-10-00219">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdulamir</surname>
<given-names>H.A.</given-names>
</name>
<name>
<surname>Abdul-Rasheed</surname>
<given-names>O.F.</given-names>
</name>
<name>
<surname>Abdulghani</surname>
<given-names>E.A.</given-names>
</name>
</person-group>
<article-title>Low oxytocin and melatonin levels and their possible role in the diagnosis and prognosis in Iraqi autistic children</article-title>
<source/>Saudi Med. J.
          <year>2016</year>
<volume>37</volume>
<fpage>29</fpage>
<lpage>36</lpage>
<pub-id pub-id-type="doi">10.15537/smj.2016.1.13183</pub-id>
<pub-id pub-id-type="pmid">26739971</pub-id>
</element-citation>
</ref>
<ref id="B51-brainsci-10-00219">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benabou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rolland</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Leblond</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Millot</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Huguet</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Delorme</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Leboyer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pagan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Callebert</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Maronde</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Heritability of the melatonin synthesis variability in autism spectrum disorders</article-title>
<source/>Sci. Rep.
          <year>2017</year>
<volume>7</volume>
<fpage>17746</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-18016-3</pub-id>
<pub-id pub-id-type="pmid">29255243</pub-id>
</element-citation>
</ref>
<ref id="B52-brainsci-10-00219">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maruani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dumas</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Beggiato</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Traut</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Peyre</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cohen-Freoua</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Amsellem</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Elmaleh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Germanaud</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Launay</surname>
<given-names>J.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Morning Plasma Melatonin Differences in Autism: Beyond the Impact of Pineal Gland Volume</article-title>
<source/>Front. Psychiatry
          <year>2019</year>
<volume>10</volume>
<fpage>11</fpage>
<pub-id pub-id-type="doi">10.3389/fpsyt.2019.00011</pub-id>
<pub-id pub-id-type="pmid">30787884</pub-id>
</element-citation>
</ref>
<ref id="B53-brainsci-10-00219">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van der Heijden</surname>
<given-names>K.B.</given-names>
</name>
<name>
<surname>Smits</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Van Someren</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Gunning</surname>
<given-names>W.B.</given-names>
</name>
</person-group>
<article-title>Idiopathic chronic sleep onset insomnia in attention-deficit/hyperactivity disorder: A circadian rhythm sleep disorder</article-title>
<source/>Chronobiol. Int.
          <year>2005</year>
<volume>22</volume>
<fpage>559</fpage>
<lpage>570</lpage>
<pub-id pub-id-type="doi">10.1081/CBI-200062410</pub-id>
<pub-id pub-id-type="pmid">16076654</pub-id>
</element-citation>
</ref>
<ref id="B54-brainsci-10-00219">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Veen</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Kooij</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Boonstra</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Gordijn</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Van Someren</surname>
<given-names>E.J.</given-names>
</name>
</person-group>
<article-title>Delayed circadian rhythm in adults with attention-deficit/hyperactivity disorder and chronic sleep-onset insomnia</article-title>
<source/>Biol. Psychiatry
          <year>2010</year>
<volume>67</volume>
<fpage>1091</fpage>
<lpage>1096</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2009.12.032</pub-id>
<pub-id pub-id-type="pmid">20163790</pub-id>
</element-citation>
</ref>
<ref id="B55-brainsci-10-00219">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bijlenga</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Van Someren</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Gruber</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bron</surname>
<given-names>T.I.</given-names>
</name>
<name>
<surname>Kruithof</surname>
<given-names>I.F.</given-names>
</name>
<name>
<surname>Spanbroek</surname>
<given-names>E.C.</given-names>
</name>
<name>
<surname>Kooij</surname>
<given-names>J.J.</given-names>
</name>
</person-group>
<article-title>Body temperature, activity and melatonin profiles in adults with attention-deficit/hyperactivity disorder and delayed sleep: A case-control study</article-title>
<source/>J. Sleep Res.
          <year>2013</year>
<volume>22</volume>
<fpage>607</fpage>
<lpage>616</lpage>
<pub-id pub-id-type="doi">10.1111/jsr.12075</pub-id>
<pub-id pub-id-type="pmid">23952346</pub-id>
</element-citation>
</ref>
<ref id="B56-brainsci-10-00219">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baird</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Coogan</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Siddiqui</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Donev</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Thome</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Adult attention-deficit hyperactivity disorder is associated with alterations in circadian rhythms at the behavioral, endocrine and molecular levels</article-title>
<source/>Mol. Psychiatry
          <year>2012</year>
<volume>17</volume>
<fpage>988</fpage>
<lpage>995</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2011.149</pub-id>
<pub-id pub-id-type="pmid">22105622</pub-id>
</element-citation>
</ref>
<ref id="B57-brainsci-10-00219">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Büber</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Çakaloz</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Işıldar</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ünlü</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bostancı</surname>
<given-names>H.E.</given-names>
</name>
<name>
<surname>Aybek</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Herken</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Increased urinary 6-hydroxymelatonin sulfate levels in attention deficit hyperactivity disorder diagnosed children and adolescent</article-title>
<source/>Neurosci. Lett.
          <year>2016</year>
<volume>617</volume>
<fpage>195</fpage>
<lpage>200</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2016.02.016</pub-id>
<pub-id pub-id-type="pmid">26879834</pub-id>
</element-citation>
</ref>
<ref id="B58-brainsci-10-00219">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dahl</surname>
<given-names>R.E.</given-names>
</name>
</person-group>
<article-title>The impact of inadequate sleep on children’s daytime cognitive function</article-title>
<source/>Semin. Pediatr. Neurol.
          <year>1996</year>
<volume>3</volume>
<fpage>44</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1016/S1071-9091(96)80028-3</pub-id>
<pub-id pub-id-type="pmid">8795841</pub-id>
</element-citation>
</ref>
<ref id="B59-brainsci-10-00219">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malow</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Adkins</surname>
<given-names>K.W.</given-names>
</name>
<name>
<surname>McGrew</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Goldman</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Fawkes</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Burnette</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Melatonin for sleep in children with autism: A controlled trial examining dose, tolerability, and outcomes</article-title>
<source/>J. Autism. Dev. Disord.
          <year>2012</year>
<volume>42</volume>
<fpage>1729</fpage>
<lpage>1737</lpage>
<pub-id pub-id-type="doi">10.1007/s10803-011-1418-3</pub-id>
<pub-id pub-id-type="pmid">22160300</pub-id>
</element-citation>
</ref>
<ref id="B60-brainsci-10-00219">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kotagal</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Broomall</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Sleep in children with autism spectrum disorder</article-title>
<source/>Pediatr. Neurol.
          <year>2012</year>
<volume>47</volume>
<fpage>242</fpage>
<lpage>251</lpage>
<pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2012.05.007</pub-id>
<pub-id pub-id-type="pmid">22964437</pub-id>
</element-citation>
</ref>
<ref id="B61-brainsci-10-00219">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Veatch</surname>
<given-names>O.J.</given-names>
</name>
<name>
<surname>Goldman</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Adkins</surname>
<given-names>K.W.</given-names>
</name>
<name>
<surname>Malow</surname>
<given-names>B.A.</given-names>
</name>
</person-group>
<article-title>Melatonin in children with autism spectrum disorders: How Does the Evidence Fit Together?</article-title>
<source/>J. Nat. Sci.
          <year>2015</year>
<volume>1</volume>
<fpage>e125</fpage>
<pub-id pub-id-type="pmid">26120597</pub-id>
</element-citation>
</ref>
<ref id="B62-brainsci-10-00219">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malow</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Marzec</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>McGrew</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Henderson</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Stone</surname>
<given-names>W.L.</given-names>
</name>
</person-group>
<article-title>Characterizing sleep in children with autism spectrum disorders: A multidimensional approach</article-title>
<source/>Sleep
          <year>2006</year>
<volume>29</volume>
<fpage>1563</fpage>
<lpage>1571</lpage>
<pub-id pub-id-type="doi">10.1093/sleep/29.12.1563</pub-id>
<pub-id pub-id-type="pmid">17252887</pub-id>
</element-citation>
</ref>
<ref id="B63-brainsci-10-00219">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schreck</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mulick</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>A.F.</given-names>
</name>
</person-group>
<article-title>Sleep problems as possible predictors of intensified symptoms of autism</article-title>
<source/>Res. Dev. Disabil.
          <year>2004</year>
<volume>25</volume>
<fpage>57</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="doi">10.1016/j.ridd.2003.04.007</pub-id>
<pub-id pub-id-type="pmid">14733976</pub-id>
</element-citation>
</ref>
<ref id="B64-brainsci-10-00219">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sikora</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Clemons</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Katz</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>The relationship between sleep problems and daytime behavior in children of different ages with autism spectrum disorders</article-title>
<source/>Pediatrics
          <year>2012</year>
<volume>130</volume>
<fpage>S83</fpage>
<lpage>S90</lpage>
<pub-id pub-id-type="doi">10.1542/peds.2012-0900F</pub-id>
<pub-id pub-id-type="pmid">23118258</pub-id>
</element-citation>
</ref>
<ref id="B65-brainsci-10-00219">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldman</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>McGrew</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>K.P.</given-names>
</name>
<name>
<surname>Richdale</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Clemons</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Malow</surname>
<given-names>B.A.</given-names>
</name>
</person-group>
<article-title>Sleep is associated with problem behaviors in children and adolescents with Autism Spectrum Disorders</article-title>
<source/>Res. Autism. Spectr. Disord.
          <year>2011</year>
<volume>5</volume>
<fpage>1223</fpage>
<lpage>1229</lpage>
<pub-id pub-id-type="doi">10.1016/j.rasd.2011.01.010</pub-id>
</element-citation>
</ref>
<ref id="B66-brainsci-10-00219">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buckley</surname>
<given-names>A.W.</given-names>
</name>
<name>
<surname>Rodriguez</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Jennison</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Buckley</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Thurm</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Swedo</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Rapid eye movement sleep percentage in children with autism compared with children with developmental delay and typical development</article-title>
<source/>Arch. Pediatr. Adolesc. Med.
          <year>2010</year>
<volume>164</volume>
<fpage>1032</fpage>
<lpage>1037</lpage>
<pub-id pub-id-type="doi">10.1001/archpediatrics.2010.202</pub-id>
<pub-id pub-id-type="pmid">21041596</pub-id>
</element-citation>
</ref>
<ref id="B67-brainsci-10-00219">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldman</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Surdyka</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Cuevas</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Adkins</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Malow</surname>
<given-names>B.A.</given-names>
</name>
</person-group>
<article-title>Defining the sleep phenotype in children with autism</article-title>
<source/>Dev. Neuropsychol.
          <year>2009</year>
<volume>34</volume>
<fpage>560</fpage>
<lpage>573</lpage>
<pub-id pub-id-type="doi">10.1080/87565640903133509</pub-id>
<pub-id pub-id-type="pmid">20183719</pub-id>
</element-citation>
</ref>
<ref id="B68-brainsci-10-00219">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giannotti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cortesi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cerquiglini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Miraglia</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Vagnoni</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sebastiani</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bernabei</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>An investigation of sleep characteristics, EEG abnormalities and epilepsy in developmentally regressed and non-regressed children with autism</article-title>
<source/>J. Autism. Dev. Disord.
          <year>2008</year>
<volume>38</volume>
<fpage>1888</fpage>
<lpage>1897</lpage>
<pub-id pub-id-type="doi">10.1007/s10803-008-0584-4</pub-id>
<pub-id pub-id-type="pmid">18483842</pub-id>
</element-citation>
</ref>
<ref id="B69-brainsci-10-00219">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krakowiak</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Goodlin-Jones</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hertz-Picciotto</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Croen</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>R.L.</given-names>
</name>
</person-group>
<article-title>Sleep problems in children with autism spectrum disorders, development al delays, and typical development: A population-based study</article-title>
<source/>J. Sleep Res.
          <year>2008</year>
<volume>17</volume>
<fpage>197</fpage>
<lpage>206</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2869.2008.00650.x</pub-id>
<pub-id pub-id-type="pmid">18482108</pub-id>
</element-citation>
</ref>
<ref id="B70-brainsci-10-00219">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiggs</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Stores</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Sleep patterns and Steep disorders in children with autistic spectrum disorders: Insights Rusing parent report and actigraphy</article-title>
<source/>Dev. Med. Child Neurol.
          <year>2004</year>
<volume>46</volume>
<fpage>372</fpage>
<lpage>380</lpage>
<pub-id pub-id-type="doi">10.1017/S0012162204000611</pub-id>
<pub-id pub-id-type="pmid">15174528</pub-id>
</element-citation>
</ref>
<ref id="B71-brainsci-10-00219">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hollway</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Aman</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Butter</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Correlates and risk markers for sleep disturbance in participants of the Autism Treatment Network</article-title>
<source/>J. Autism. Dev. Disord.
          <year>2013</year>
<volume>43</volume>
<fpage>2830</fpage>
<lpage>2843</lpage>
<pub-id pub-id-type="doi">10.1007/s10803-013-1830-y</pub-id>
<pub-id pub-id-type="pmid">23624832</pub-id>
</element-citation>
</ref>
<ref id="B72-brainsci-10-00219">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Hubbard</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Fabes</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Adam</surname>
<given-names>J.B.</given-names>
</name>
</person-group>
<article-title>Sleep disturbances and correlates of children with autism spectrum disorders</article-title>
<source/>Child Psychiatry Hum. Dev.
          <year>2006</year>
<volume>37</volume>
<fpage>179</fpage>
<lpage>191</lpage>
<pub-id pub-id-type="doi">10.1007/s10578-006-0028-3</pub-id>
<pub-id pub-id-type="pmid">17001527</pub-id>
</element-citation>
</ref>
<ref id="B73-brainsci-10-00219">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sivertsen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Posserud</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Gillberg</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lundervold</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Hysing</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Sleep problems in children with autism spectrum problems: A longitudinal population-based study</article-title>
<source/>Autism
          <year>2012</year>
<volume>16</volume>
<fpage>139</fpage>
<lpage>150</lpage>
<pub-id pub-id-type="doi">10.1177/1362361311404255</pub-id>
<pub-id pub-id-type="pmid">21478225</pub-id>
</element-citation>
</ref>
<ref id="B74-brainsci-10-00219">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corkum</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tannock</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Moldofsky</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Sleep disturbances in children with attention-deficit/hyperactivity disorder</article-title>
<source/>J. Am. Acad. Child Adolesc. Psychiatry
          <year>1998</year>
<volume>37</volume>
<fpage>637</fpage>
<lpage>646</lpage>
<pub-id pub-id-type="doi">10.1097/00004583-199806000-00014</pub-id>
<pub-id pub-id-type="pmid">9628084</pub-id>
</element-citation>
</ref>
<ref id="B75-brainsci-10-00219">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen-Zion</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ancoli-Israel</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Sleep in children with attention-deficit hyperactivity disorder (ADHD): A review of naturalistic and stimulant intervention studies</article-title>
<source/>Sleep Med. Rev.
          <year>2004</year>
<volume>8</volume>
<fpage>379</fpage>
<lpage>402</lpage>
<pub-id pub-id-type="doi">10.1016/j.smrv.2004.06.002</pub-id>
<pub-id pub-id-type="pmid">15336238</pub-id>
</element-citation>
</ref>
<ref id="B76-brainsci-10-00219">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lecendreux</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Konofal</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bouvard</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Falissard</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mouren-Siméoni</surname>
<given-names>M.C.</given-names>
</name>
</person-group>
<article-title>Sleep and Alertness in Children with ADHD</article-title>
<source/>J. Child Psychol. Psychiatry
          <year>2000</year>
<volume>41</volume>
<fpage>803</fpage>
<lpage>812</lpage>
<pub-id pub-id-type="doi">10.1111/1469-7610.00667</pub-id>
<pub-id pub-id-type="pmid">11039692</pub-id>
</element-citation>
</ref>
<ref id="B77-brainsci-10-00219">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirov</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kinkelbur</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Banaschewski</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Rothenberger</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Sleep patterns in children with attention-deficit/hyperactivity disorder, tic disorder, and comorbidity</article-title>
<source/>J. Child Psychol. Psychiatry
          <year>2007</year>
<volume>48</volume>
<fpage>561</fpage>
<lpage>570</lpage>
<pub-id pub-id-type="doi">10.1111/j.1469-7610.2007.01729.x</pub-id>
<pub-id pub-id-type="pmid">17537072</pub-id>
</element-citation>
</ref>
<ref id="B78-brainsci-10-00219">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirov</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Uebel</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Albrecht</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Banaschewski</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Rothenberger</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Two faces of REM sleep in normal and psychopathological development</article-title>
<source/>Eur. Psychiatry
          <year>2011</year>
<volume>26</volume>
<fpage>422</fpage>
<lpage>423</lpage>
<pub-id pub-id-type="doi">10.1016/S0924-9338(11)72130-7</pub-id>
</element-citation>
</ref>
<ref id="B79-brainsci-10-00219">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Golan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Shahar</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ravid</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pillar</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Sleep disorders and daytime sleepiness in children with attention-deficit/ hyperactive disorder</article-title>
<source/>Sleep
          <year>2004</year>
<volume>27</volume>
<fpage>261</fpage>
<lpage>266</lpage>
<pub-id pub-id-type="doi">10.1093/sleep/27.2.261</pub-id>
<pub-id pub-id-type="pmid">15124720</pub-id>
</element-citation>
</ref>
<ref id="B80-brainsci-10-00219">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cortese</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Faraone</surname>
<given-names>S.V.</given-names>
</name>
<name>
<surname>Konofal</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lecendreux</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Sleep in children with attention-deficit/hyperactivity disorder: Meta-analysis of subjective and objective studies</article-title>
<source/>J. Am. Acad. Child Adolesc. Psychiatry
          <year>2009</year>
<volume>48</volume>
<fpage>894</fpage>
<lpage>908</lpage>
<pub-id pub-id-type="doi">10.1097/CHI.0b013e3181ae09c9</pub-id>
<pub-id pub-id-type="pmid">19625983</pub-id>
</element-citation>
</ref>
<ref id="B81-brainsci-10-00219">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Micoulaud Franchi</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Chenini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gachet</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jaussent</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Dauvilliers</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Restless legs syndrome and iron deficiency in adults with attention-deficit/hyperactivity disorder</article-title>
<source/>Sleep
          <year>2019</year>
<volume>42</volume>
<fpage>zsz027</fpage>
<pub-id pub-id-type="doi">10.1093/sleep/zsz027</pub-id>
<pub-id pub-id-type="pmid">30722056</pub-id>
</element-citation>
</ref>
<ref id="B82-brainsci-10-00219">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Fantozzi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Villafranca</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tacchi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ricci</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ruglioni</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Inguaggiato</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pfanner</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cortese</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Effects of melatonin in children with attention-deficit/hyperactivity disorder with sleep disorders after methylphenidate treatment</article-title>
<source/>Neuropsychiatr. Dis. Treat.
          <year>2019</year>
<volume>15</volume>
<fpage>663</fpage>
<lpage>667</lpage>
<pub-id pub-id-type="doi">10.2147/NDT.S193891</pub-id>
<pub-id pub-id-type="pmid">30880992</pub-id>
</element-citation>
</ref>
<ref id="B83-brainsci-10-00219">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mick</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Biederman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jetton</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Faraone</surname>
<given-names>S.V.</given-names>
</name>
</person-group>
<article-title>Sleep disturbances associated with attention deficit hyperactivity disorder: The impact of psychiatric comorbidity and pharmacotherapy</article-title>
<source/>J. Child Adolesc. Psychopharmacol.
          <year>2000</year>
<volume>10</volume>
<fpage>223</fpage>
<lpage>231</lpage>
<pub-id pub-id-type="doi">10.1089/10445460050167331</pub-id>
<pub-id pub-id-type="pmid">11052412</pub-id>
</element-citation>
</ref>
<ref id="B84-brainsci-10-00219">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ironside</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Davidson</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Corkum</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Circadian motor activity affected by stimulant medication in children with attention-deficit/hyperactivity disorder</article-title>
<source/>J. Sleep Res.
          <year>2010</year>
<volume>19</volume>
<fpage>546</fpage>
<lpage>551</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2869.2010.00845.x</pub-id>
<pub-id pub-id-type="pmid">20629940</pub-id>
</element-citation>
</ref>
<ref id="B85-brainsci-10-00219">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schachter</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Pham</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>King</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Langford</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Moher</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>How efficacious and safe is short- acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis</article-title>
<source/>CMAJ
          <year>2001</year>
<volume>165</volume>
<fpage>1475</fpage>
<lpage>1488</lpage>
<pub-id pub-id-type="pmid">11762571</pub-id>
</element-citation>
</ref>
<ref id="B86-brainsci-10-00219">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galland</surname>
<given-names>B.C.</given-names>
</name>
<name>
<surname>Tripp</surname>
<given-names>E.G.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>B.J.</given-names>
</name>
</person-group>
<article-title>The sleep of children with attention deficit hyperactivity disorder on and off methylphenidate: A matched case-control study</article-title>
<source/>J. Sleep Res.
          <year>2009</year>
<volume>19</volume>
<fpage>366</fpage>
<lpage>373</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2869.2009.00795.x</pub-id>
<pub-id pub-id-type="pmid">20050995</pub-id>
</element-citation>
</ref>
<ref id="B87-brainsci-10-00219">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smits</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Nagtegaal</surname>
<given-names>E.E.</given-names>
</name>
<name>
<surname>van der Heijden</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Coenen</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Kerkhof</surname>
<given-names>G.A.</given-names>
</name>
</person-group>
<article-title>Melatonin for chronic sleep onset insomnia in children: A randomized placebo-controlled trial</article-title>
<source/>J. Child Neurol.
          <year>2001</year>
<volume>16</volume>
<fpage>86</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="doi">10.1177/088307380101600204</pub-id>
<pub-id pub-id-type="pmid">11292231</pub-id>
</element-citation>
</ref>
<ref id="B88-brainsci-10-00219">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pelham</surname>
<given-names>W.E.</given-names>
</name>
<name>
<surname>Gnagy</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Burrows-Maclean</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fabiano</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Morrisey</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Chronis</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Forehand</surname>
<given-names>G.L.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Hoffman</surname>
<given-names>M.T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Once-a-day Concerta methylphenidate versus three-times daily methylphenidate in laboratory and natural settings</article-title>
<source/>Pediatrics
          <year>2001</year>
<volume>107</volume>
<fpage>E105</fpage>
<pub-id pub-id-type="doi">10.1542/peds.107.6.e105</pub-id>
<pub-id pub-id-type="pmid">11389303</pub-id>
</element-citation>
</ref>
<ref id="B89-brainsci-10-00219">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Golnik</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Ireland</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Complementary alternative medicine for children with autism: A physician survey</article-title>
<source/>J. Autism. Dev. Disord.
          <year>2009</year>
<volume>39</volume>
<fpage>996</fpage>
<lpage>1005</lpage>
<pub-id pub-id-type="doi">10.1007/s10803-009-0714-7</pub-id>
<pub-id pub-id-type="pmid">19280328</pub-id>
</element-citation>
</ref>
<ref id="B90-brainsci-10-00219">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cortesi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Giannotti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sebastiani</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Panunzi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Valente</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Controlled-release melatonin, singly and combined with cognitive behavioral therapy, for persistent insomnia in children with autism spectrum disorders: A randomized placebo-controlled trial</article-title>
<source/>J. Sleep Res.
          <year>2012</year>
<volume>21</volume>
<fpage>700</fpage>
<lpage>709</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2869.2012.01021.x</pub-id>
<pub-id pub-id-type="pmid">22616853</pub-id>
</element-citation>
</ref>
<ref id="B91-brainsci-10-00219">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Owens</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Pharmacotherapy of pediatric insomnia</article-title>
<source/>J. Am. Acad. Child Adolesc. Psychiatry
          <year>2009</year>
<volume>48</volume>
<fpage>99</fpage>
<lpage>107</lpage>
<pub-id pub-id-type="pmid">20040822</pub-id>
</element-citation>
</ref>
<ref id="B92-brainsci-10-00219">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hutchins</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Melatonin: A panacea for desperate parents? (Hype or truth)</article-title>
<source/>Arch. Dis. Child
          <year>2005</year>
<volume>90</volume>
<fpage>986</fpage>
<lpage>987</lpage>
<pub-id pub-id-type="doi">10.1136/adc.2005.075218</pub-id>
</element-citation>
</ref>
<ref id="B93-brainsci-10-00219">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giannotti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cortesi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cerquiglini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bernabei</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism</article-title>
<source/>J. Autism. Dev. Disord.
          <year>2006</year>
<volume>36</volume>
<fpage>741</fpage>
<lpage>752</lpage>
<pub-id pub-id-type="doi">10.1007/s10803-006-0116-z</pub-id>
<pub-id pub-id-type="pmid">16897403</pub-id>
</element-citation>
</ref>
<ref id="B94-brainsci-10-00219">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garstang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wallis</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems</article-title>
<source/>Child Care Health Dev.
          <year>2006</year>
<volume>32</volume>
<fpage>585</fpage>
<lpage>589</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2214.2006.00616.x</pub-id>
<pub-id pub-id-type="pmid">16919138</pub-id>
</element-citation>
</ref>
<ref id="B95-brainsci-10-00219">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andersen</surname>
<given-names>I.M.</given-names>
</name>
<name>
<surname>Kaczmarska</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>McGrew</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Malow</surname>
<given-names>B.A.</given-names>
</name>
</person-group>
<article-title>Melatonin for Insomnia in Children With Autism Spectrum Disorders</article-title>
<source/>J. Child Neurol.
          <year>2008</year>
<volume>23</volume>
<fpage>482</fpage>
<lpage>485</lpage>
<pub-id pub-id-type="doi">10.1177/0883073807309783</pub-id>
<pub-id pub-id-type="pmid">18182647</pub-id>
</element-citation>
</ref>
<ref id="B96-brainsci-10-00219">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wasdell</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Jan</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Bomben</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Rietveld</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Tai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>M.D.</given-names>
</name>
</person-group>
<article-title>A randomized, placebo -controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities</article-title>
<source/>J. Pineal. Res.
          <year>2008</year>
<volume>44</volume>
<fpage>57</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="doi">10.1111/j.1600-079X.2007.00528.x</pub-id>
<pub-id pub-id-type="pmid">18078449</pub-id>
</element-citation>
</ref>
<ref id="B97-brainsci-10-00219">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wirojanan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jacquemont</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Diaz</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bacalman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Anders</surname>
<given-names>T.F.</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Goodlin-Jones</surname>
<given-names>B.L.</given-names>
</name>
</person-group>
<article-title>The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome</article-title>
<source/>J. Clin. Sleep Med.
          <year>2009</year>
<volume>5</volume>
<fpage>145</fpage>
<lpage>150</lpage>
<pub-id pub-id-type="doi">10.5664/jcsm.27443</pub-id>
<pub-id pub-id-type="pmid">19968048</pub-id>
</element-citation>
</ref>
<ref id="B98-brainsci-10-00219">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wright</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sims</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Smart</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Alwazeer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alderson-Day</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Allgar</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Whitton</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tomlinson</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jardine</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behavior management strategies: A randomised controlled crossover trial</article-title>
<source/>J. Autism. Dev. Disord.
          <year>2011</year>
<volume>41</volume>
<fpage>175</fpage>
<lpage>184</lpage>
<pub-id pub-id-type="doi">10.1007/s10803-010-1036-5</pub-id>
<pub-id pub-id-type="pmid">20535539</pub-id>
</element-citation>
</ref>
<ref id="B99-brainsci-10-00219">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gringras</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gamble</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Wiggs</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Williamson</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Sutcliffe</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Montgomery</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Whitehouse</surname>
<given-names>W.P.</given-names>
</name>
<name>
<surname>Choonara</surname>
<given-names>I.</given-names>
</name>
<collab>MENDS Study Group</collab>
<etal></etal>
</person-group>
<article-title>Melatonin for sleep problems in children with neurodevelopmental disorders: Randomised double masked placebo controlled trial</article-title>
<source/>BMJ
          <year>2012</year>
<volume>345</volume>
<fpage>e6664</fpage>
<pub-id pub-id-type="doi">10.1136/bmj.e6664</pub-id>
<pub-id pub-id-type="pmid">23129488</pub-id>
</element-citation>
</ref>
<ref id="B100-brainsci-10-00219">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gringras</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nir</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Breddy</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Frydman-Marom</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Findling</surname>
<given-names>R.L.</given-names>
</name>
</person-group>
<article-title>Efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder</article-title>
<source/>J. Am. Acad. Child Adolesc. Psychiatry
          <year>2017</year>
<volume>56</volume>
<fpage>948</fpage>
<lpage>957</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaac.2017.09.414</pub-id>
<pub-id pub-id-type="pmid">29096777</pub-id>
</element-citation>
</ref>
<ref id="B101-brainsci-10-00219">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maras</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schroder</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Malow</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Findling</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Breddy</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nir</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shahmoon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zisapel</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Gringras</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Long-term efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder</article-title>
<source/>J. Child Adolesc. Psychopharmacol.
          <year>2018</year>
<volume>28</volume>
<fpage>699</fpage>
<lpage>710</lpage>
<pub-id pub-id-type="doi">10.1089/cap.2018.0020</pub-id>
<pub-id pub-id-type="pmid">30132686</pub-id>
</element-citation>
</ref>
<ref id="B102-brainsci-10-00219">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schroder</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Malow</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Maras</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Melmed</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Findling</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Breddy</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nir</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shahmoon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zisapel</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Gringras</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Pediatric Prolonged-Release Melatonin for Sleep in Children with Autism Spectrum Disorder: Impact on Child Behavior and Caregiver’s Quality of Life</article-title>
<source/>J. Autism. Dev. Disord.
          <year>2019</year>
<volume>49</volume>
<fpage>3218</fpage>
<lpage>3230</lpage>
<pub-id pub-id-type="doi">10.1007/s10803-019-04046-5</pub-id>
<pub-id pub-id-type="pmid">31079275</pub-id>
</element-citation>
</ref>
<ref id="B103-brainsci-10-00219">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malow</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Findling</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Schroder</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Maras</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Breddy</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nir</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zisapel</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Gringras</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Sleep, Growth, and Puberty After Two Years of Prolonged-Release Melatonin in Children With Autism Spectrum Disorder</article-title>
<source/>J. Am. Acad. Child Adolesc. Psychiatry
          <year>2020</year>
<pub-id pub-id-type="doi">10.1016/j.jaac.2019.12.007</pub-id>
</element-citation>
</ref>
<ref id="B104-brainsci-10-00219">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ayyash</surname>
<given-names>H.F.</given-names>
</name>
<name>
<surname>Preece</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Morton</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cortese</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Melatonin for sleep disturbance in children with neurodevelopmental disorders: Prospective observational naturalistic study</article-title>
<source/>Expert Rev. Neurother.
          <year>2015</year>
<volume>15</volume>
<fpage>711</fpage>
<lpage>717</lpage>
<pub-id pub-id-type="doi">10.1586/14737175.2015.1041511</pub-id>
<pub-id pub-id-type="pmid">25938708</pub-id>
</element-citation>
</ref>
<ref id="B105-brainsci-10-00219">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braam</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Keijzer</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Struijker Boudier</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Didden</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Smits</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Curfs</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>CYP1A2 polymorphisms in slow melatonin metabolisers: A possible relationship with autism spectrum disorder?</article-title>
<source/>J. Intellect. Disabil. Res.
          <year>2013</year>
<volume>57</volume>
<fpage>993</fpage>
<lpage>1000</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2788.2012.01595.x</pub-id>
<pub-id pub-id-type="pmid">22823064</pub-id>
</element-citation>
</ref>
<ref id="B106-brainsci-10-00219">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tzischinsky</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Lavie</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Melatonin possesses time-dependent hypnotic effects</article-title>
<source/>Sleep
          <year>1994</year>
<volume>17</volume>
<fpage>638</fpage>
<lpage>645</lpage>
<pub-id pub-id-type="doi">10.1093/sleep/17.7.638</pub-id>
<pub-id pub-id-type="pmid">7846463</pub-id>
</element-citation>
</ref>
<ref id="B107-brainsci-10-00219">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossignol</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>R.E.</given-names>
</name>
</person-group>
<article-title>Melatonin in autism spectrum disorders: A systematic review and meta-analysis</article-title>
<source/>Dev. Med. Child Neurol.
          <year>2011</year>
<volume>53</volume>
<fpage>783</fpage>
<lpage>792</lpage>
<pub-id pub-id-type="doi">10.1111/j.1469-8749.2011.03980.x</pub-id>
<pub-id pub-id-type="pmid">21518346</pub-id>
</element-citation>
</ref>
<ref id="B108-brainsci-10-00219">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jan</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>O’Donnell</surname>
<given-names>M.E.</given-names>
</name>
</person-group>
<article-title>Use of melatonin in the treatment of paediatric sleep disorders</article-title>
<source/>J. Pineal. Res.
          <year>1996</year>
<volume>21</volume>
<fpage>193</fpage>
<lpage>199</lpage>
<pub-id pub-id-type="doi">10.1111/j.1600-079X.1996.tb00286.x</pub-id>
<pub-id pub-id-type="pmid">8989717</pub-id>
</element-citation>
</ref>
<ref id="B109-brainsci-10-00219">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilens</surname>
<given-names>T.E.</given-names>
</name>
<name>
<surname>Biederman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Spencer</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder</article-title>
<source/>J. Am. Acad. Child Adolesc. Psychiatry
          <year>1994</year>
<volume>33</volume>
<fpage>424</fpage>
<lpage>426</lpage>
<pub-id pub-id-type="doi">10.1097/00004583-199403000-00018</pub-id>
<pub-id pub-id-type="pmid">8169189</pub-id>
</element-citation>
</ref>
<ref id="B110-brainsci-10-00219">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gruber</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wiebe</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Montecalvo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Brunetti</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Amsel</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Carrier</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Impact of sleep restriction on neurobehavioral functioning of children with attention deficit hyperactivity disorder</article-title>
<source/>Sleep
          <year>2011</year>
<volume>34</volume>
<fpage>315</fpage>
<lpage>323</lpage>
<pub-id pub-id-type="doi">10.1093/sleep/34.3.315</pub-id>
<pub-id pub-id-type="pmid">21358848</pub-id>
</element-citation>
</ref>
<ref id="B111-brainsci-10-00219">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoebert</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>van der Heijden</surname>
<given-names>K.B.</given-names>
</name>
<name>
<surname>van Geijlswijk</surname>
<given-names>I.M.</given-names>
</name>
<name>
<surname>Smits</surname>
<given-names>M.G.</given-names>
</name>
</person-group>
<article-title>Long-term follow-up of melatonin treatment in children with ADHD and chronic sleep onset insomnia</article-title>
<source/>J. Pineal. Res.
          <year>2009</year>
<volume>47</volume>
<fpage>1</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1111/j.1600-079X.2009.00681.x</pub-id>
<pub-id pub-id-type="pmid">19486273</pub-id>
</element-citation>
</ref>
<ref id="B112-brainsci-10-00219">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van der Heijden</surname>
<given-names>K.B.</given-names>
</name>
<name>
<surname>Smits</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Van Someren</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Ridderinkhof</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Gunning</surname>
<given-names>W.B.</given-names>
</name>
</person-group>
<article-title>Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia</article-title>
<source/>J. Am. Acad. Child Adolesc. Psychiatry
          <year>2007</year>
<volume>46</volume>
<fpage>233</fpage>
<lpage>241</lpage>
<pub-id pub-id-type="doi">10.1097/01.chi.0000246055.76167.0d</pub-id>
<pub-id pub-id-type="pmid">17242627</pub-id>
</element-citation>
</ref>
<ref id="B113-brainsci-10-00219">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weiss</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Wasdell</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Bomben</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Rea</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>R.D.</given-names>
</name>
</person-group>
<article-title>Sleep hygiene and melatonin treatment for children and adolescents with ADHD and initial insomnia</article-title>
<source/>J. Am. Acad. Child Adolesc. Psychiatry
          <year>2006</year>
<volume>45</volume>
<fpage>512</fpage>
<lpage>519</lpage>
<pub-id pub-id-type="doi">10.1097/01</pub-id>
<pub-id pub-id-type="pmid">16670647</pub-id>
</element-citation>
</ref>
<ref id="B114-brainsci-10-00219">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>TjonPian Gi</surname>
<given-names>C.V.</given-names>
</name>
<name>
<surname>Broeren</surname>
<given-names>J.P.A.</given-names>
</name>
<name>
<surname>Starreveld</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>A Versteegh</surname>
<given-names>F.G.</given-names>
</name>
</person-group>
<article-title>Melatonin for treatment of sleeping disorders in children with attention deficit/hyperactivity disorder: A preliminary open label study</article-title>
<source/>Eur. J. Pediatr.
          <year>2003</year>
<volume>162</volume>
<fpage>554</fpage>
<lpage>555</lpage>
<pub-id pub-id-type="doi">10.1007/s00431-003-1207-x</pub-id>
<pub-id pub-id-type="pmid">12783318</pub-id>
</element-citation>
</ref>
<ref id="B115-brainsci-10-00219">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mohammadi</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Mostafavi</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Keshavarz</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Eshraghian</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Hosseinzadeh</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Hosseinzadeh-Attar</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Kooshesh</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Chamari</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Akhondzadeh</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Melatonin effects in methylphenidate treated children with attention deficit hyperactivity disorder: A randomized double blind clinical trial</article-title>
<source/>Iran J. Psychiatry
          <year>2012</year>
<volume>7</volume>
<fpage>87</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="pmid">22952551</pub-id>
</element-citation>
</ref>
<ref id="B116-brainsci-10-00219">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mostafavi</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Mohammadi</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Hosseinzadeh</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Eshraghian</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Akhondzadeh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hosseinzadeh-Attar</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Ranjbar</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kooshesh</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Keshavarz</surname>
<given-names>S.A.</given-names>
</name>
</person-group>
<article-title>Dietary intake, growth and development of children with ADHD in a randomized clinical trial of Ritalin and Melatonin co-administration: Through circadian cycle modification or appetite enhancement?</article-title>
<source/>Iran J. Psychiatry
          <year>2012</year>
<volume>7</volume>
<fpage>114</fpage>
<lpage>119</lpage>
<pub-id pub-id-type="pmid">23139692</pub-id>
</element-citation>
</ref>
<ref id="B117-brainsci-10-00219">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwichtenberg</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Malow</surname>
<given-names>B.A.</given-names>
</name>
</person-group>
<article-title>Melatonin Treatment in Children with Developmental Disabilities</article-title>
<source/>Sleep Med. Clin.
          <year>2015</year>
<volume>10</volume>
<fpage>181</fpage>
<lpage>187</lpage>
<pub-id pub-id-type="doi">10.1016/j.jsmc.2015.02.008</pub-id>
<pub-id pub-id-type="pmid">26055866</pub-id>
</element-citation>
</ref>
<ref id="B118-brainsci-10-00219">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Geijlswijk</surname>
<given-names>I.M.</given-names>
</name>
<name>
<surname>Mol</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Egberts</surname>
<given-names>T.C.</given-names>
</name>
<name>
<surname>Smits</surname>
<given-names>M.G.</given-names>
</name>
</person-group>
<article-title>Evaluation of sleep, puberty and mental health in children with long-term melatonin treatment for chronic idiopathic childhood sleep onset insomnia</article-title>
<source/>Psychopharmacology
          <year>2011</year>
<volume>216</volume>
<fpage>111</fpage>
<lpage>120</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-011-2202-y</pub-id>
<pub-id pub-id-type="pmid">21340475</pub-id>
</element-citation>
</ref>
<ref id="B119-brainsci-10-00219">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Babineau</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Goodwin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>FPIN’s clinical inquiries. Medications for insomnia treatment in children</article-title>
<source/>Am. Fam. Physician
          <year>2008</year>
<volume>77</volume>
<fpage>358</fpage>
<lpage>359</lpage>
<pub-id pub-id-type="pmid">18297962</pub-id>
</element-citation>
</ref>
<ref id="B120-brainsci-10-00219">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carr</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wasdell</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Tai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rietveld</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Jan</surname>
<given-names>J.E.</given-names>
</name>
</person-group>
<article-title>Long-term effectiveness outcome of melatonin therapy in children with treatment-resistant circadian rhythm sleep disorders</article-title>
<source/>J. Pineal. Res.
          <year>2007</year>
<volume>43</volume>
<fpage>351</fpage>
<lpage>359</lpage>
<pub-id pub-id-type="doi">10.1111/j.1600-079X.2007.00485.x</pub-id>
<pub-id pub-id-type="pmid">17910603</pub-id>
</element-citation>
</ref>
<ref id="B121-brainsci-10-00219">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Howes</surname>
<given-names>O.D.</given-names>
</name>
<name>
<surname>Rogdaki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Findon</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Wichers</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Charman</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>King</surname>
<given-names>B.H.</given-names>
</name>
<name>
<surname>Loth</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>McAlonan</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>McCracken</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Parr</surname>
<given-names>J.R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology</article-title>
<source/>J. Psychopharmacol.
          <year>2018</year>
<volume>32</volume>
<fpage>3</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="doi">10.1177/0269881117741766</pub-id>
<pub-id pub-id-type="pmid">29237331</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<table-wrap id="brainsci-10-00219-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">brainsci-10-00219-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>Melatonin level assessment in the group of patients with autism spectrum disorder (ASD).</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">References</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Number of Patients</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Material</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Results</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Nir I et al., 1995 [<xref ref-type="bibr" rid="B49-brainsci-10-00219">49</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">10 patients with ASD<break></break>5 controls</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">serum</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1. Similar results of mean daily melatonin levels were measured in serum in the group of patients with ASD and the control group.<break></break>2. Patients with ASD showed lower melatonin levels at night and higher during the day relative to the control group.</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Tordjman S et al., 2005 [<xref ref-type="bibr" rid="B47-brainsci-10-00219">47</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">49 patients with ASD<break></break>88 controls</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">urine</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1. Low melatonin levels were observed in 63% (31/49) of patients with ASD.<break></break>2. In pre-pubertal period, a reduction in 6-SM was apparently observed in patients with ASD relative to the control group.</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Melke J et al., 2008 [<xref ref-type="bibr" rid="B37-brainsci-10-00219">37</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">43 patients with ASD<break></break>34 parents<break></break>48 controls</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">plasma</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1. Low melatonin levels were observed in 65% of patients with ASD.<break></break>2. There is a genetic potential for reduced melatonin levels in ASD, as asymptomatic parents also have abnormally low melatonin levels.<break></break>3. The results suggest that in patients with ASD and low melatonin levels we can get sleep improvement through supplementation.</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Tordjman S et al., 2012 [<xref ref-type="bibr" rid="B43-brainsci-10-00219">43</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">43 patients with ASD<break></break>26 controls</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">urine</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with ASD showed lower levels of nocturnal 6-SM excretion in urine than those in the control group.</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Pagan C et al., 2014 [<xref ref-type="bibr" rid="B41-brainsci-10-00219">41</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">278 patients with ASD<break></break>129 unaffected siblings<break></break>377 parents<break></break>416 controls</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">plasma</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Melatonin levels in patients with ASD and their relatives were significantly lower than in the control group.</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Abdulamir HA et al., 2016 [<xref ref-type="bibr" rid="B50-brainsci-10-00219">50</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">60 patients with ASD<break></break>26 controls</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">serum</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1. Patients with ASD presented lower levels of melatonin than the control group.<break></break>2. A relationship has been demonstrated between the severity of autism and lower melatonin levels.</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Benabou M et al., 2017 [<xref ref-type="bibr" rid="B51-brainsci-10-00219">51</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">157 patients with ASD<break></break>100 unaffected siblings<break></break>264 parents</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">plasma</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Phenotypic variation and changes in melatonin levels in patients with ASD and their families are the result of environmental and genetic factors.</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Braam W et al., 2018 [<xref ref-type="bibr" rid="B11-brainsci-10-00219">11</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">60 mothers of a child with ASD <break></break>15 controls</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">urine</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1. Mothers of children with ASD had significantly lower levels of 6-SM in urine compared to the control group.<break></break>2. Mothers of children with ASD were older at the time of child birth compared to mothers of children without ASD.</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Maruani A et al., 2019 [<xref ref-type="bibr" rid="B52-brainsci-10-00219">52</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">78 patients with ASD<break></break>90 unaffected relatives<break></break>47 controls</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">plasma</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1. Patients with ASD presented lower levels of melatonin than their relatives and people from the control group.<break></break>2. Lower levels of melatonin were observed in relatives of patients with ASD, however, the result was not statistically significant.</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="brainsci-10-00219-t002" orientation="portrait" position="float">
<object-id pub-id-type="pii">brainsci-10-00219-t002_Table 2</object-id>
<label>Table 2</label>
<caption>
<p>Melatonin level assessment in the group of patients with attention-deficit/hyperactivity disorder (ADHD).</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">References</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Number of Patients</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Material</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Results</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Van der Heijden KB et al., 2005 [<xref ref-type="bibr" rid="B53-brainsci-10-00219">53</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">87 patients with ADHD-SOI <break></break>33 patients with ADHD-noSOI</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">saliva</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ADHD patients with concomitant chronic idiopathic insomnia at the onset of sleep presented significantly delayed DLMO and sleep phase relative to the ADHD-noSOI group.</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Van Veen MM et al., 2010 [<xref ref-type="bibr" rid="B54-brainsci-10-00219">54</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">34 patients with ADHD<break></break>38 controls</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">saliva</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1. Melatonin production in the ADHD group began 83 min later than the control group.<break></break>2. Patients with ADHD showed less effective sleep and longer sleep delay.</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Baird AL et al., 2012 [<xref ref-type="bibr" rid="B56-brainsci-10-00219">56</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">13 patients with ADHD<break></break>19 controls</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">saliva</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1. In the group of patients with ADHD disturbed rhythm of melatonin relative to the control group was observed.</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Bijlenga D et al., 2013 [<xref ref-type="bibr" rid="B55-brainsci-10-00219">55</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">12 patients with ADHD<break></break>12 controls</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">saliva</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1. In the group of people with ADHD, DLMO was delayed by about 1.5 h relative to the control group.<break></break>2. An average one hour longer interval between the onset of DLMO and onset of sleep was observed in subjects with ADHD relative to the control group.</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Büber A et al., 2016 [<xref ref-type="bibr" rid="B57-brainsci-10-00219">57</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">27 patients with ADHD<break></break>28 controls</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">urine</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Patients with ADHD had significantly higher levels of total 24-h urinary excretion of 6-OH MS than controls.</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>(ADHD-SOI)—ADHD-related sleep-onset insomnia, (ADHD-noSOI)—ADHD without sleep-onset insomnia.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="brainsci-10-00219-t003" orientation="portrait" position="float">
<object-id pub-id-type="pii">brainsci-10-00219-t003_Table 3</object-id>
<label>Table 3</label>
<caption>
<p>Melatonin supplementation in ASD patients.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">References</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Study Design</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Number of Patients</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Age</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Diagnosis</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Melatonin Dosage</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Time of Melatonin Supplementation (before Bedtime)</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Duration of Melatonin Supplementation</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gupta R, et al. 2005 [<xref ref-type="bibr" rid="B92-brainsci-10-00219">92</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Retrospective study</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">9</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2–11 years</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ASD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2.5–5 mg</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">45 min</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Giannotti F, et al. 2006 [<xref ref-type="bibr" rid="B93-brainsci-10-00219">93</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Open label</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">20</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2.6–9.1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ASD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3 mg<break></break>(1 mg FR and 2 mg CR)–6mg</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">30–40 min</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2 years</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Garstrang J, et al. 2006 [<xref ref-type="bibr" rid="B94-brainsci-10-00219">94</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">DB-RCT</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">7</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4–16</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ASD<break></break>ADHD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">5 mg</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4 weeks</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Andersen IM, et al. 2008 [<xref ref-type="bibr" rid="B95-brainsci-10-00219">95</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Retrospective study</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">107</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2−18</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ASD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.75–6 mg</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">30–60 min</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1.8 ± 1.4 years</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Wasdell MB, et al. 2008 [<xref ref-type="bibr" rid="B96-brainsci-10-00219">96</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">DB-RCT</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">50</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2.05−17.81</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Severe intellectual loss<break></break>Cerebral palsy<break></break>Epilepsy<break></break>Visual impairment<break></break>Lack of mobility <break></break>ASD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">5 mg CR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">20–30 min</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">10 days</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Wirojanan J, et al. 2009 [<xref ref-type="bibr" rid="B97-brainsci-10-00219">97</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">DB-RCT</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">12</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2–15.25</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ASD<break></break>Fragile X syndrome</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3 mg</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">30 min</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2 weeks</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Wright B, et al. 2011 [<xref ref-type="bibr" rid="B98-brainsci-10-00219">98</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">DB-RCT</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">16</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4–16</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ASD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2–10 mg</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">30–40 min</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3 months</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cortesi F, et al. 2012 [<xref ref-type="bibr" rid="B90-brainsci-10-00219">90</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">DB-RCT </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">74</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4–10</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ASD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3 mg CR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">21:00</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">12 weeks</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gringras P, et al. 2012 [<xref ref-type="bibr" rid="B99-brainsci-10-00219">99</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">DB-RCT</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">51</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3.7–15</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">DD alone<break></break>DD and epilepsy<break></break>DD and ASD<break></break>DD, ASD, epilepsy<break></break>DD and “other”</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.5–12 mg</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">45 min</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">12 weeks</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Malow B, et al.2012 [<xref ref-type="bibr" rid="B59-brainsci-10-00219">59</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Open label</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">24</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3−10</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ASD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1–6 mg</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">30 min</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">14 weeks</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Goldman S, et al. 2014 [<xref ref-type="bibr" rid="B48-brainsci-10-00219">48</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Open label</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">9</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3−8</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ASD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1–3 mg</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">30 min</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3–6 weeks</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gringras P, et al. 2017 [<xref ref-type="bibr" rid="B100-brainsci-10-00219">100</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">DB-RCT</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">58</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2−17</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ASD<break></break>SMS</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2–5 mg of PedPRM</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">13 weeks</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Maras A, et al. 2018 [<xref ref-type="bibr" rid="B101-brainsci-10-00219">101</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">DB-RCT</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">51</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2−17.5</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ASD<break></break>Neurogenetic disorders</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2–10 mg of PedPRM</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">30−60 min</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">52 weeks</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Schroder CM, et al. 2019 [<xref ref-type="bibr" rid="B102-brainsci-10-00219">102</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">DB-RCT</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">58</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2−17.5</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ASD<break></break>SMS</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2–5 mg of PedPRM</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">30−60 min</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">13 weeks</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Malow BA, et al. 2020 [<xref ref-type="bibr" rid="B103-brainsci-10-00219">103</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">DB-RCT</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">74</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2−17.5</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ASD<break></break>SMS</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2–10 mg of PedPRM</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">30−60 min</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">104 weeks</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>DB-RCT—double blind, randomized control trial, CR—controlled-release, FR—fast release, DD—developmental delay, PedPRM—pediatric-appropriate 3 mm diameter prolonged release melatonin minitablet, SMS—Smith–Magenis syndrome.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="brainsci-10-00219-t004" orientation="portrait" position="float">
<object-id pub-id-type="pii">brainsci-10-00219-t004_Table 4</object-id>
<label>Table 4</label>
<caption>
<p>Effects of melatonin supplementation in ASD patients.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">References</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Sleep Latency</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Total Duration of Sleep </th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Behavior</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Night−Wakings</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gupta R, et al. 2005 [<xref ref-type="bibr" rid="B92-brainsci-10-00219">92</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Garstrang J, et al. 2006 [<xref ref-type="bibr" rid="B94-brainsci-10-00219">94</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Wasdell MB, et al. 2008 [<xref ref-type="bibr" rid="B96-brainsci-10-00219">96</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Wirojanan J, et al. 2009 [<xref ref-type="bibr" rid="B97-brainsci-10-00219">97</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">−</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Wright B, et al. 2011 [<xref ref-type="bibr" rid="B98-brainsci-10-00219">98</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">−</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gringras P, et al. 2012 [<xref ref-type="bibr" rid="B99-brainsci-10-00219">99</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Cortesi F, et al. 2012 [<xref ref-type="bibr" rid="B90-brainsci-10-00219">90</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Malow B, et al.2012 [<xref ref-type="bibr" rid="B59-brainsci-10-00219">59</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">−</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">−</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Goldman S, et al. 2014 [<xref ref-type="bibr" rid="B48-brainsci-10-00219">48</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Gringras P, et al. 2017 [<xref ref-type="bibr" rid="B100-brainsci-10-00219">100</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Maras A, et al. 2018 [<xref ref-type="bibr" rid="B101-brainsci-10-00219">101</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Schroder CM, et al.2019 [<xref ref-type="bibr" rid="B102-brainsci-10-00219">102</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>(+) improvement (<bold>−</bold>) without any significant difference.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="brainsci-10-00219-t005" orientation="portrait" position="float">
<object-id pub-id-type="pii">brainsci-10-00219-t005_Table 5</object-id>
<label>Table 5</label>
<caption>
<p>Melatonin supplementation in patients with ADHD.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">References</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Study Design</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Number of Patients</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Age</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Diagnosis</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Melatonin Dosage</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Time of Melatonin Supplementation (before Bedtime)</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Duration of Melatonin Supplementation</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Weiss MD, et al. 2006 [<xref ref-type="bibr" rid="B113-brainsci-10-00219">113</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>DB-RCT</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">19</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">6.5–14.7 years</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ADHD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">5 mg</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">20 min</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">10 days</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Van der Heijden KB, et al. 2007 [<xref ref-type="bibr" rid="B112-brainsci-10-00219">112</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>DB-RCT</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">53</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">6–12</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ADHD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3–6 mg FR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">19:00</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4 weeks</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hoebert M, et al. 2009 [<xref ref-type="bibr" rid="B111-brainsci-10-00219">111</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>DB-RCT</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">94</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">12.39 ± 0.25</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ADHD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3–6 mg</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">18:30–23:00</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3.66 ± 0.12 year</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mohammadi MR, et al. 2012 [<xref ref-type="bibr" rid="B115-brainsci-10-00219">115</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>DB-RCT</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">26</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">7–12</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ADHD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3–6 mg</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">8 weeks</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mostafavi SA, et al. 2012 [<xref ref-type="bibr" rid="B116-brainsci-10-00219">116</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>DB-RCT</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">26</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">7–12</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ADHD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">3–6 mg</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">8 weeks</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Ayyash HF, et al. 2015 [<xref ref-type="bibr" rid="B104-brainsci-10-00219">104</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Prospective, observational, naturalistic study</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">45</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">6.3 ± 1.7 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Intellectual disability ASD ADHD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2.5–10 mg</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">30 min</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">326 days</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Masi G, et al.2019 [<xref ref-type="bibr" rid="B82-brainsci-10-00219">82</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Observational, naturalistic study</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">74</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">11.6 ± 2.2 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ADHD</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1–5 mg</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1–2 h</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">4 weeks–12 months</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>DB-RCT—double blind, randomized control trial, FR—fast release.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="brainsci-10-00219-t006" orientation="portrait" position="float">
<object-id pub-id-type="pii">brainsci-10-00219-t006_Table 6</object-id>
<label>Table 6</label>
<caption>
<p>-Effects of melatonin supplementation in patients with ADHD.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">References</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Sleep Latency</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Total Duration of Sleep</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Behavior</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Cognition</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Quality of Life</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Frequent Awakenings</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Van der Heijden KB, et al. 2007 [<xref ref-type="bibr" rid="B112-brainsci-10-00219">112</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">−</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">−</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">−</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hoebert M, et al. 2009 [<xref ref-type="bibr" rid="B111-brainsci-10-00219">111</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mostafavi SA, et al. 2012 [<xref ref-type="bibr" rid="B116-brainsci-10-00219">116</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Mohammadi MR, et al. 2012 [<xref ref-type="bibr" rid="B115-brainsci-10-00219">115</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">−</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Ayyash HF, et al. 2015 [<xref ref-type="bibr" rid="B104-brainsci-10-00219">104</xref>]</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">+</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>(+)—improvement (−)—without any significant differences.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>